Advertisement

Therapie der akuten und chronischen Herzinsuffizienz mit Herzglykosiden

  • E. Erdmann
Part of the Handbuch der inneren Medizin book series (INNEREN, volume 9 / 4)

Zusammenfassung

Es gibt eine Reihe von historischen Berichten und Hinweisen über die Herzwirksamkeit von Pflanzenextrakten, die wahrscheinlich auf die kardioaktiven Glykoside zu beziehen sind (Moe u. Farah 1975; Kraupp 1980). William Withering aber gebührt das Verdienst der ersten eingehenden und genauen Beschreibung der Wirkungen und Nebenwirkungen der Herzglykoside, wobei er in seinem berühmten Buch: “An Account of the Foxglove and Some of its Medical Uses” (1785) sowohl exakte Dosierungsrichtlinien vorstellte als auch auf die Gefahren der unkritischen Anwendung hinwies. Er verordnete die Digitalisextrakte seiner Meinung nach meist als Diuretikum, die kardiale Wirkung war ihm aber zumindest bekannt, da er schrieb: “It has a power over the motion of the heart to a degree yet unobserved in any other medicine, and this power may be converted to salutary ends.” Ein ausführlicher historischer Abriß der Herzglykoside und ihrer Anwendung findet sich bei Greeff u. Schadewaldt (1981).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abshagen U, Rennekamp H, Kuhlmann J (1976) Effects of pretreatment with spironolactone on pharmacokinetics of 4‴-methyldigoxin in man. Naunyn Schmiedebergs Arch ×Pharmacol 292:87–92Google Scholar
  2. Akera T (1977) Membrane adenosinetriphosphatase : a digitalis receptor? Science 198:569–574PubMedGoogle Scholar
  3. Akera T, Brody TM (1978) The role of Na+, K+-ATPase in the inotropic action of digitalis. Pharmacol Rev 29:187–220Google Scholar
  4. Akera T, Baskin SI, Tobin T, Brody TM (1973) Ouabain: temporal relationship between the inotropic effect and the in vitro binding to, and dissociation from (Na+ + K+)-activated ATPase. Naunyn Schmiedebergs Arch Pharmacol 277:151–12PubMedGoogle Scholar
  5. Akera T, Temma K, Wiest SA, Brody TM (1978) Reduction of the equilibrium binding of cardiac glycosides and related compounds to Na+, K+-ATPase as a possible mechanism for the potassium-induced reversal of their toxicity. Naunyn Schmiedebergs Arch Pharmacol 304:157–165PubMedGoogle Scholar
  6. Al-Ismail SAD, Whittaker JA (1978) Systolic time interval to predict doxorubicin cardiotoxicity. Lancet 2:1315Google Scholar
  7. Allen JC, Harris RA, Schwartz A (1971) The nature of the transport ATPase-digitalis complex. J Mol Cell Cardiol 3:297–300PubMedGoogle Scholar
  8. Allonen H (1977) The effect of phenytoin on the tissue concentrations of digoxin in the rat. Acta Pharmacol Toxicol 1:481–488Google Scholar
  9. Almeyda J, Levantine A (1973) Cutaneous reactions to cardiovascular drugs. Br J Dermatol 88:313–324PubMedGoogle Scholar
  10. Alousi AA, Farah AE, Lesher GY, Opalka CJ (1979) Cardiotonic activity of amrinone-Win 40680 (5-Amino-3,4′-biphyridin-6-(lH)-one). Circ Res 45:666–677PubMedGoogle Scholar
  11. Amlie JP, Storstein L (1979) Digitoxin induced changes in contractility and electrophysiology in the dog heart in sites in relation to serum concentrations after a single intravenous dose. In: Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 149–157Google Scholar
  12. Amlie JP, Storstein L, Heldaas O (1979) Correlation between pharmacokinetics and inotropic and electrophysiologic responses to digitoxin in the intact dog. J Cardiovasc Pharmacol 1:529–540PubMedGoogle Scholar
  13. Amsterdam E, De Maria A, Hughes J, Hurley E, Lurie A, Williams D, Miller R, Mason D (1976) Myocardial infarction shock: mechanisms and management. In: Mason D (ed) Congestive heart failure. Yorke Medical Books, Dun-Donnelley New York, pp 365–396Google Scholar
  14. Anderson GJ, Bailey JC, Reiser J, Freeman A (1976) Electrophysiological observations on the digitalis-potassium interaction in canine purkinje fibers. Circ Res 39:717–723PubMedGoogle Scholar
  15. Andersson K-E, Nyberg L, Dencker H, Göthlin J (1975) Absorption of digoxin in man after oral and intrasigmoid administration studied by portal vein catherization. Eur J Clin Pharmacol 9:39–47PubMedGoogle Scholar
  16. Applefeld MM, Adir J, Crouthhamel WG, Roffman DS (1981) Digoxin pharmacokinetics in congestive heart failure. J Clin Pharmacol 21:114–120PubMedGoogle Scholar
  17. Ardenne v M (1975) Messungen zur Wirksamkeit von perlingual gegebenem g-Strophan-thin nach der Methode des kardialen Anspannungsindex. Acta Cardiol 10/11:3–16Google Scholar
  18. Ardenne v M, Rieger F (1972) Theoretische und experimentelle Grundlagen zur außerge-wöhnlichen Pharmakokinetik des g-Strophanthin. Arzneimittelforsch 22:3–28Google Scholar
  19. Ardenne M v, Ardenne A v (1975) Messungen zur Wirksamkeit von perlingual gegebenem g-Strophanthin nach der Methode des kardialen Anspannungsindex. Cardiol Bull (Acta Cardiol) 10:193–206Google Scholar
  20. Arnim Th v, Krawietz W, Vogt W, Erdmann E (1980) Is the determination of serum digoxin concentration useful for the diagnosis of digitalis toxicity? Int J Clin Pharmacol Ther Toxicol 18:261–268Google Scholar
  21. Arnold SB, Byrd RC, Meister W, Melmon D, Cheitlin M, Bristow JD, Parmey WW, Chatterjee K (1980) Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 303:1443–1448PubMedGoogle Scholar
  22. Aronson JK (1980) Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 5:137–149PubMedGoogle Scholar
  23. Augsberger A (1951) Quantitatives zur Therapie mit Herzglykosiden. 1. Mitteilung: Die Variabilität von Glykosidbedarf und -toleranz. Med Welt 47:1471–1475Google Scholar
  24. Aust PE, Belz GG (1980) Die Bedeutung des Glykosidspiegels bei der Digitalistherapie. Med Klin 75:650–653PubMedGoogle Scholar
  25. Avery GS (1973) Check list to potentially clinically important interactions. Drugs 5:187–199PubMedGoogle Scholar
  26. Bachour G, Hochrein (1975) Digitalis beim akuten Herzinfarkt. Dtsch Med Wochenschr 100:2417–2422PubMedGoogle Scholar
  27. Baedeker W, Wirtzfeld A (1973) Rhythmusstörungen bei Digitalis-Intoxikation. Int J Clin Pharmacol 8:292–301PubMedGoogle Scholar
  28. Balcerzak SP, Christakis J, Lewis RP, Olson HM, Malspeis L (1978) Systolic time intervals in monitoring adriamycin-induced cardiotoxicity. Cancer Treat Rep 62:893–899PubMedGoogle Scholar
  29. Balcon R, Hoy J, Sowton E (1968) Haemodynamic effects of rapid digitalization following acute myocardial infarction. Br Heart J 30:373–376PubMedGoogle Scholar
  30. Baligadoo S, Chiche P (1981) Frequency of toxicity of digitoxin and factors predisposing to toxicity in ambulatory patients: a multifactorial correspondence analysis of 2120 outpatients. In: Kochsiek K, Rietbrock N (Hrsg) Digitalistherapie bei Herzinsuffizienz. Urban & Schwarzenberg, München, S 118–126Google Scholar
  31. Bashour FA, Edmonson RE, Gupta DN, Prati R (1968) Treatment of digitalis toxicity by diphenylhydantoin (Dilantin). Dis Chest 53:263–270PubMedGoogle Scholar
  32. Beck OA, Krämer K-D, Hochrein H (1974) Verlauf einer suizidalen Digoxin-Intoxikation mit Hyperkaliämie. Dtsch Med Wochenschr 99:756–764PubMedGoogle Scholar
  33. Beckmann H, Belz GG, Quellhorst E (1979) Meproscillarin bei gleichzeitiger Nierenund Herzinsuffizienz. Med Klinik 74:1761–1766Google Scholar
  34. Beermann B, Hellström K, Rosen A (1971) Fate of orally administered 3H-digitoxin in man with special reference to the absorption. Circulation 43, 852–857PubMedGoogle Scholar
  35. Beermann B, Hellström K, Rosen A (1972) The absorption of orally administered (12a-3H)-digoxin in man. Clin Sci 43:507–511PubMedGoogle Scholar
  36. Beiser GD, Epstein SE, Stampfer M, Robinson B, Braunwald E (1968) Effects of ouabain on the hemodynamic response to exercise in patients with mitral stenosis in normal sinus rhythm. Studies on Digitalis 278:131–137Google Scholar
  37. Beller GA, Hood WB, Smith ThW, Abelmann WH, Wacker WEC (1974a) Correlation of serum magnesium levels and cardiac digitalis intoxication. Am J Cardiol 33:225–229Google Scholar
  38. Beller GA, Conroy J, Smith TW (1974b) Altered myocardial Na+, K+-ATPase activity following acute myocardial ischemia. Circulation 40 : III-11Google Scholar
  39. Belz GG (1974) Regularisierung von Vorhofflimmern. Med Klin 69:1152–1156PubMedGoogle Scholar
  40. Belz GG, Brech WJ (1974) Plasmaspiegel und Kumulationsverhalten von Proscillaridin bei Niereninsuffizienz. Klin Wochenschr 52:640–644PubMedGoogle Scholar
  41. Belz GG, Erbel R (1979) Einfluß von Digitoxin auf die systolischen Zeitintervalle beim Menschen. In: Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 158–160Google Scholar
  42. Belz GG, Heinz N (1977) The influence of polar and non-polar digoxin and digitoxin metabolites on the 86Rb+-uptake of human erythrocytes of guinea pig papillary muscles. Arzneimittelforsch 27:653–659PubMedGoogle Scholar
  43. Belz GG, Kleeberg UR (1975) Plasma half life of β-methyl digoxin following repetitive application in man. Klin Wochenschr 53:491–492PubMedGoogle Scholar
  44. Belz G, Nübling H (1975) Half life in plasma following repetitive application of β-acetyl-digoxin in man. Klin Wochenschr 53:543–544PubMedGoogle Scholar
  45. Belz GG, Nübling H, Schmidt-Wiederkehr P, Franz HE (1974) Plasmakonzentrationen und Elimination von Methylproscillaridin bei Niereninsuffizienz. Klin Wochenschr 52:1078–1081PubMedGoogle Scholar
  46. Belz GG, Schreiter H, Wolf GK (1976a) Pharmacokinetics and pharmacodynamics of methylproscillaridin in healthy man. Eur J Clin Pharmacol 10:101–108Google Scholar
  47. Belz GG, Nübling H, Belz G (1976b) Plasma concentrations during repeated intravenous and oral methyl-proscillaridin application in man. Arzneimittelforsch 26:277–278Google Scholar
  48. Belz GG, Erbel R, Schumann K, Gilfrich HJ (1978) Dose-response relationships and plasma concentrations of digitalis glycosides in man. Eur J Clin Pharmacol 13:103–111PubMedGoogle Scholar
  49. Belz GG, Czermak E, Belz G (1979) Die zeitliche Kinetik der Wirkung von Digitoxin und β-Acetyl-Digoxin nach oraler Applikation beim Menschen. Z Kardiol 68:77–81PubMedGoogle Scholar
  50. Belz GG, Aust PE, Munkes R (1981) Digoxin plasma concentrations and nifedipine. Lancet 2:844–845Google Scholar
  51. Belz GG, Doering W, Aust PE, Heinz M, Matthews J, Schneider B (1982) Quinidine-digoxin interaction: cardiac efficacy of elevated serum digoxin concentration. Clin Pharmacol Ther 31:548–554PubMedGoogle Scholar
  52. Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi AA (1978) Hemodynamic assessment of amrinone. A new inotropic agent. N Engl J Med 299:1373–1377PubMedGoogle Scholar
  53. Bentfeld M, Lullmann H, Peters T, Proppe D (1977) Interdependence of ion transport and the action of ouabain in heart muscle. Br J Pharmacol 61:19–27PubMedGoogle Scholar
  54. Besch HR, Allen JC, Glick G, Schwartz A (1970) Correlation between the inotropic action of ouabain and its effects on subcellular enzyme systems from canine myocardium. J Pharmacol Exp Ther 171:1–13PubMedGoogle Scholar
  55. Beyer C, Lüllmann H, Peters Th, Zahorsky R (1981) Tierexperimentelle Untersuchungen zur Wirksamkeit und Toxizität von klassischen und semisynthetischen Herzglykosiden. Z Kardiol 70:290Google Scholar
  56. Biddle TL, Weintraub M, Lasagna L (1978) Relationship of serum and myocardial digoxin concentration to electrocardiographic estimation of digoxin intoxication. J Clin Pharmacol 18:10–15PubMedGoogle Scholar
  57. Bigger JT (1981) Management of arrhythmias. In: Braunwald E (ed). Heart disease. Saunders, Philadelphia, pp 691–743Google Scholar
  58. Bigger JT, Hoffman B (1980) Antiarrhythmic drugs. In: Goodman-Gilman A, Goodman L, Gilman A (eds) The pharmacological basis of therapeutics. MacMillan, New York, pp 176–210Google Scholar
  59. Binnion PF (1978) Comparative pharmakokinetics of various digoxin preparations in man. In: Bodem G, Dengler D (eds) Cardiac glycosides. Springer, Berlin Heidelberg New York, pp 199–206Google Scholar
  60. Binnion PF, Aristarco M (1974) The absorption of digoxin tablets. Clin Pharmacol Ther 16:807–812PubMedGoogle Scholar
  61. Blaustein MP (1977) Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypotheses. Am J Physiol 232:C165-C173PubMedGoogle Scholar
  62. Blumenthal HP (1979) Pharmacokinetics models for digitoxin. In: Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 52–60Google Scholar
  63. Bluschke V, Bonn R, Greeff K (1976) Increase in the (Na++K+)-ATPase activity in heart muscle after chronic treatment with digitoxin or potassium deficient diet. Eur J Pharmacol 37:189–191PubMedGoogle Scholar
  64. Bodem G (1977) Prospektive Studien mit Digitalis. Verh Dtsch Ges Inn Med 83:76–83PubMedGoogle Scholar
  65. Bodem G (1980) Überwachung der Digitalistherapie. Med Welt 31:1–4Google Scholar
  66. Bodem G, Gilfrich HJ (1973) Methoden zur Bestimmung von Digoxin und Digitoxin im Blut und ihre klinische Bedeutung. Klin Wochenschr 51:57–62PubMedGoogle Scholar
  67. Bodem G, Ochs H (1979) Metabolimus und Ausscheidung von Digitoxin. In: Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 101–113Google Scholar
  68. Bodem G, Wirth K, Gernand E, Dengler HJ (1974) Pharmacokinetics and metabolism of a-acetyldigoxin in man. Arch Int Pharmacodyn Ther 208:102–116PubMedGoogle Scholar
  69. Bodem G, Wirth K, Ochs H (1975) Die biologische Verfügbarkeit von Digoxin. Inn Med 2:110–115Google Scholar
  70. Bodem G, Gilfrich HJ, Aulepp H, Ochs H, Dengler HJ (1977a) Klinische und pharmakologische Untersuchungen zur Digitalisintoxikation. Klin Wochenschr 55:13–21Google Scholar
  71. Bodem G, Boldt U, Ochs H (1977b) Konzentrationen von Digoxin und Beta-Methyldigoxin im Liquor und Plasma. Klin Wochenschr 55:355–356Google Scholar
  72. Bolte H-D (1977) Wirkungsmechanismus der herzwirksamen Glykoside unter pathophysiologischen Bedingungen. Verh Dtsch Ges Inn Med 83:19–28PubMedGoogle Scholar
  73. Bolte H-D (1980) Behandlung der Herzinsuffizienz mit Vasodilatantien. Internist 21:753–759PubMedGoogle Scholar
  74. Bolte H-D (Hrsg) (1981) Katecholamine und Vasodilatantien bei Herzinsuffizienz. Springer, Berlin Heidelberg New York, S 1–100Google Scholar
  75. Bolte H-D, Lankisch PG, Buchesfeld R, Larbig D (1972) Speichelelektrolyte (Natrium, Kalium, Calcium) bei Herzglykosidbehandlung. Verh Dtsch Ges Inn Med 78:1603–1606PubMedGoogle Scholar
  76. Bolte H-D, Buckesfeld R, Lankisch PK, Larbig D (1973) Speichelelektrolyte und Glykosidintoxikation. Verh Dtsch Ges Inn Med 79:1047–1050PubMedGoogle Scholar
  77. Bolte H-D, Erdmann E, Cyran J (1981) Untersuchungen zum Wirkungsbeginn und Wirkungsmaximum von Digitoxin nach intravenöser Injektion bei Patienten. In: Kochsiek K, Rietbrock N (Hrsg) Digitalistherapie bei Herzinsuffizienz. Urban & Schwarzenberg, München, S 88–92Google Scholar
  78. Bonelli J, Haydl H, Hruby K, Kaik G (1978) The pharmacokinetics of digoxin in patients with manifest hyperthyroidism and after normalization of thyroid function. Int J Clin Pharmacol 16:302–306Google Scholar
  79. Bonelli J, Rameis H, Waginger H (1981) Digoxin concentration in cerebrospinal fluid — a study carried out after 9 days of treatment with β-methyldigoxin or β-acetyldigoxin. Int J Clin Pharmacol 19:93–95Google Scholar
  80. Bonn R, Greeff K (1978) The effect of chronic administration of digitoxin on the activity of the myocardial (Na+ +K+)-ATPase in guinea-pigs. Arch Int Pharmacodyn Ther 233:53–64PubMedGoogle Scholar
  81. Bower J, Mengle H (1936) The addition effect of calcium and digitalis. Am Med Assoc 106:1151–1153Google Scholar
  82. Brachtel R, Gilfrich HJ (1977) Die intestinale Resorption von Digoxin bei Patienten mit progressiver Sklerodermie. Klin Wochenschr 55:439–444PubMedGoogle Scholar
  83. Brass H, Philipps H (1970) Die Elimination von α-Acetyldigoxin und k-Strophanthin bei Niereninsuffizienz. Klin Wochenschr 48:972–978PubMedGoogle Scholar
  84. Braunwald E, Bloodwell RD, Goldberg LI, Morrow AG (1961) Studies on Digitalis. IV. Observations in man on the effects of digitalis preparations on the contractility of the non-failing heart and on total vascular resistance. J Clin Invest 40:52–59PubMedGoogle Scholar
  85. Braunwald E, Brockenbrough EC, Frye RL (1962) Studies on digitalis. V. Comparison of the effects of ouabain on left ventricular dynamics in valvular aortic stenosis and hypertrophic subaortic stenosis. Circulation 26:166–17PubMedGoogle Scholar
  86. Breckenridge A (1982) Vasodilators in heart failure. Br Med J 284:765–766Google Scholar
  87. Breithaupt H (1979) Behandlung der Herzinsuffizienz. Med Welt 30:1531–1539PubMedGoogle Scholar
  88. Bristow MR (1980) Anthracycline cardiotoxicity. In: Bristow MR (ed) Drug-induced heart disease. Elsevier/North-Holland Biomedical Press, Amsterdam, pp 191–215Google Scholar
  89. Brock A (1975) Binding of digitoxin to human serum proteins: influence of pH on the binding to human albumin. Acta Pharmacol Toxicol 36:13–24Google Scholar
  90. Brody TM, Akera T (1977) Relations among Na+ +K+-ATPase activity, sodium pump activity, transmembrane sodium movement, and cardiac contractility. Fed Proc 36:2219–2224PubMedGoogle Scholar
  91. Brown DD, Juhl RP (1976) Decreased bioavailability of digoxin due to antacids and kaolin-pectin. N Engl J Med 295:1034–1037PubMedGoogle Scholar
  92. Brown L, Werdan K, Erdmann E (1983) Consequences of specific 3H-ouabain binding to guinea pig left atria and cardiac cell membranes. Biochem Pharmacol 32:423–435PubMedGoogle Scholar
  93. Burman SO (1965) Digitalis and thoracic surgery. J Thorac Cardiovasc Surg 50:873–881PubMedGoogle Scholar
  94. Burwell CS, Neigbors DW, Regen EM (1927) The effect of digitalis upon the output of the heart in normal man. J Clin Invest 5:125–140PubMedGoogle Scholar
  95. Bussmann W-D (1978) Therapie der schweren Herzinsuffizienz. Dtsch Med Wochenschr 103:1500–1502Google Scholar
  96. Butler VP, Lindenbaum J (1975) Serum digitalis measurements in the assessment of digitalis resistance and sensitivity. Am J Med 58:460–469PubMedGoogle Scholar
  97. Butler VP, Smith ThW, Schmidt DH, Haber E (1977) Immunological reversal of the effects of digoxin. Fed Proc 36:2235–2241PubMedGoogle Scholar
  98. Caldwell PC, Keynes RD (1959) The effect of ouabain on the efflux of sodium from a squid giant axon. J Physiol 148:8P-9PGoogle Scholar
  99. Catell M, Gold H (1938) The influence of digitalis glycosides on the force of contraction of mammalian cardiac muscle. J Pharmacol Exp Ther 62:116–125Google Scholar
  100. Chamberlain DA, White RJ, Howard MR, Smith TW (1970) Plasma digoxin concentrations in patients with atrial fibrillation. Br Med J 3:429–432PubMedGoogle Scholar
  101. Chavaz A, Balant D, Fabre SJ (1974) Influence del(’)âge sur la digoxinémie et la digitalisation. Schweiz Med Wochenschr 104:1823–1825PubMedGoogle Scholar
  102. Chen C, Fricke U (1981) Effect of potassium on the action of semisynthetic digitalis glycosides in guinea pig isolated cardiac muscle. Naunyn Schmiedebergs Arch Pharmacol 316: R36Google Scholar
  103. Chen S-S, Friedman HS (1980) Alteration of digoxin pharmacokinetics by single dose of quinidine. JAMA 244:669–672PubMedGoogle Scholar
  104. Chopra D, Janson P, Sawin C (1977) Insensitivity of digoxin associated with hypocalcemia. N Engl J Med 296:917–918PubMedGoogle Scholar
  105. Clasen R, Kemmeter H, Gilfrich HJ (1979) Biologische Verfügbarkeit von Digoxin und Beta-Acetyldigoxin nach Einmalapplikation. Dtsch Med Wochenschr 104:543–546PubMedGoogle Scholar
  106. Clausen T, Hansen O (1977) Active Na — K-transport and the rate of ouabain binding. The effect of insulin and other stimuli on skeletal muscle and adipocytes. J Physiol 270:415–430PubMedGoogle Scholar
  107. Cocco G, Strozzi C (1978) Digitalistherapie bei Niereninsuffizienten. Inform Arzt 9:59–70Google Scholar
  108. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedGoogle Scholar
  109. Cohn JN, Tristani EE, Khatri IM (1969) Cardiac and peripheral vascular effects of digitalis in clinical cardiogenic shock. Am Heart J 78:318–330PubMedGoogle Scholar
  110. Cohn K, Selzer A, Kersh ES, Karpman LS, Goldschlager N (1975) Variability of hemodynamic response to acute digitalization in chronic cardiac failure due to cardiomyopathy and coronary artery disease. Am J Cardiol 35:461–468PubMedGoogle Scholar
  111. Coleman HN (1967) Role of acetylstrophanthidin in augmenting myocardial oxygen consumption. Circ Res 21:487–495PubMedGoogle Scholar
  112. Coltart JD, Güllern HG, Billingham M, Goldman RH, Stinson EB, Kaiman SM, Harrison DC (1974) Physiological distribution of digoxin in human heart. Br Med J 4:733–736PubMedGoogle Scholar
  113. Colucci W, Wayne AR, Williams G, Rude R, Holman B, Konstam M, Wynne J, Mudge G, Braunwald E (1981) Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med 305:185–190PubMedGoogle Scholar
  114. Conn RD (1965) Diphenylhydantoin sodium in cardiac arrhythmias. N Engl J Med 272:277–282PubMedGoogle Scholar
  115. Conn RD, Kennedy JW, Blackmon JR, Wash S (1967) The hemodynamic effects of diphenylhydantoin. Am Heart J 73:500–505PubMedGoogle Scholar
  116. Covell JW, Braunwald E, Ross J, Sonnenblick EH (1966) Studies on digitalis. XVI. Effects on myocardial oxygen consumption. J Clin Invest 45:1535–1541PubMedGoogle Scholar
  117. Croxson MS, Ibbertson HK (1975) Serum digoxin in patients with thyroid disease. Br Med J 3:566–568PubMedGoogle Scholar
  118. Curfman GD, Crowley TJ, Smith TW (1977) Throid-induced alterations in myocardial sodium- and potassium-activated adenosine triphosphatase, monovalent cation active transport, and cardiac glycoside binding. J Clin Invest 59:586–590PubMedGoogle Scholar
  119. Dahl JL, Hokin LE (1974) The sodium-potassium adenosinetriphosphatase. Annu Rev Biochem 43:327–356PubMedGoogle Scholar
  120. Darsee JR, Braunwald E (1980) Disease of the percardium. In: Braunwald E (ed) Heart disease. Saunders, Philadelphia, pp 1517–1582Google Scholar
  121. Daut J, Rüdel R (1980) The electrogenic pump current in guinea-pig myocardium. J Physiol (Lond) 305:22PGoogle Scholar
  122. Davidson C, Gibson D (1973) Clinical significance of positive inotropic action of digoxin in patients with left ventricular disease. Br Heart J 35:970–976PubMedGoogle Scholar
  123. Delius W (1966) Diphenylhydantoin-Therapie bei Herzrhythmusstörungen. Med Klin 61:1836–1838PubMedGoogle Scholar
  124. Demers HG (1980) Neue Erkenntnisse in der Digitalistherapie. Diagn Intensivther 9:95–99Google Scholar
  125. DeMots H, Rahimtoola SH, McAnulty JH, Porter GA (1978) Effects of ouabain on coronary and systemic vascular resistance and myocardial oxygen consumption in patients without heart failure. Am J Cardiol 41:88–93PubMedGoogle Scholar
  126. Dengler HH, Bodem G, With K (1973a) Pharmacokinetic and metabolic studies with lanatoside C, and β-acetyldigoxin and digoxin in man. In: Pharmacology and the future of man, vol 3. Proc 5th Int Congr Pharmacol, San Francisco 1972. Karger, Basel, pp 112–126Google Scholar
  127. Dengler HJ, Bodem G, Wirth K (1973b) Pharmakokinetische Untersuchungen mit 3H-Digoxin und 3H-Lanatoxid beim Menschen. Arzneimittelforsch 32:64–74Google Scholar
  128. DePover A, Godfraind T (1979) Interaction of ouabain with (Na+ +K+)-ATPase from human heart and from guinea pig heart. Biochem Pharmacol 28:30–3056Google Scholar
  129. Dettli L (1976) Arzneimitteldosierung bei Niereninsuffizienz. In: Kümmerle HP, Garrett ER, Spitzy KH (Hrsg) Klinische Pharmakologie. Urban & Schwarzenberg, München, S 83–89Google Scholar
  130. Deutsch S, Dalen J (1969) Indications for prophylactic digitalisation. Anaesthesiology 30:648–652Google Scholar
  131. Dhingra RC, Amat-Y-Leon F, Wyndham C, Wu D, Denes P, Rosen KM (1975) The electrophysiological effects of ouabain on sinus node and atrium in man. J Clin Invest 56:555–562PubMedGoogle Scholar
  132. Dimant J, Merrit W (1976) Serum digoxin levels in elderly nursing home patients : Appraisal of routine periodic measurements. J Am Geriatr Soc 26:378–379Google Scholar
  133. Ditchey RV, Karliner JS (1981) Safety of electrical cardioversion in patients without digitalis toxicity. Ann Intern Med 95:676–679PubMedGoogle Scholar
  134. Djonlagić H, Kurnatowski H-A von, Diederich K-W (1974) Bidirektionale Tachykardie bei Digitalisbehandlung. Dtsch Med Wochenschr 99:502–509PubMedGoogle Scholar
  135. Dobbs SM, Kenyon WI, Dobbs RJ (1977) Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. Br Med J 19:749–752Google Scholar
  136. Doering W (1979) Quinidine-digoxin interaction: pharmacokinetics, underlying mechanism and clinical implications. N Engl J Med 301:400–404PubMedGoogle Scholar
  137. Doering W (1981) Chinin-Digoxin-Interaktion. Der informierte Arzt 13:56–58Google Scholar
  138. Doering W, Blümel E (1978) Vereinfachte Serum-Digoxin-Bestimmung mit einem Jod-125-Solid-Phase-Test. Klin Wochenschr 56:497–502PubMedGoogle Scholar
  139. Doering W, König E (1977) Digitalisintoxikation. Ursachen, Diagnose, Prophylaxe. Dtsch Med Wochenschr 102:579–585PubMedGoogle Scholar
  140. Doering W, König E (1978) Anstieg der Digoxinkonzentration im Serum unter Chinidin-medikation. Med Klin 73:1085–1088PubMedGoogle Scholar
  141. Doering W, König E (1979) Die Therapie der Herzinsuffizienz. Neuere Aspekte der Glykosidtherapie. Pharmakotherapie 2:85–94Google Scholar
  142. Doering W, Isbary J, König E (1981) Besteht eine klinisch relevante Interaktion zwischen Digoxin und diversen Antiphlogistika? Z Kardiol 70:289Google Scholar
  143. Doherty J (1973) The influence of renal function on digoxin metabolism. In: Storstein O (ed) Symposium on digitalis. Gyldendal Norsk, Oslo, pp 168–178Google Scholar
  144. Doherty JE (1982) The digoxin-quinidine-interaction. Annu Rev Med 33:163–170PubMedGoogle Scholar
  145. Doherty J, Perkins W (1966) Digoxin metabolism in hypo- and hyperthyroidism. Ann Intern Med 64:489–507PubMedGoogle Scholar
  146. Doherty JE, Flanigen WJ, Murphy ML, Bulloch RT, Dalrymple GL, Beard OW, Perkins WH (1970) Tritiated digoxin. Circulation 42:867–873PubMedGoogle Scholar
  147. Doherty JE, Dalrymple GV, Murphy ML, Kane JJ, Bissett JK DeSoyza N (1977a) Pharmacokinetics of digoxin. Fed Proc 36:2242–2246Google Scholar
  148. Doherty JE, Kane JJ, Phillips JR, Adamson JS (1977b) Digitalis in pulmonary heart disease (Cor pulmonale). Drugs 13:142–151Google Scholar
  149. Doherty JE, Straub KD, Murphy ML, Soyza N de, Bissett JK, Kane JJ (1980) Digoxin-quinidine interaction. Changes in canine tissue concentration from steady state with quinidine. Am J Cardiol 45:1196–1210PubMedGoogle Scholar
  150. Dollery C, George C, Orme M (1974) Drug interactions affecting cardiovascular therapy. In: Cheff L, Petrie J (eds) Clinical effects of interaction between drugs. Excerpta Medica, Amsterdam, pp 117–152Google Scholar
  151. Dowdy EG, Fabian LW (1963) Ventricular arrhythmias induced by succinyl-choline in digitalized patients. Anaesth Analg 42:501–513Google Scholar
  152. Dransfeld H, Greeff K, Berger H, Cautius V (1966) Die verschiedene Empfindlichkeit der Na+ + K+-aktivierten ATPase des Herz- und Skelettmuskels gegen k-Strophan-thin. Naunyn Schmiedebergs Arch Pharmakol 254:225–234Google Scholar
  153. Dukes MNG (1980) Drugs affecting autonomic functions or the extrapyramidal system. In: Dukes MNG (ed) Meyler’s side effects of drugs, 9th edn. Excerpta Medica. Amsterdam, pp 213–233Google Scholar
  154. Dutta S, Goswami S, Lindower JO, Marks BH (1968) Subcellular distribution of digoxin-H3 in isolated guinea-pig and rat hearts. J Pharmacol Exp Ther 159:324–334PubMedGoogle Scholar
  155. Dwenger A (1973) Chemie, Biochemie und klinische Pharmakologie der Digitalisglykoside. Arzneimittelforsch 23:1439–1446PubMedGoogle Scholar
  156. Dyckner T, De Faire U, Wester PO (1977) Intracellular electrolytes in cardiac and skeletal muscle in fatal digitalis intoxication. Br Heart J 38:1029–1032Google Scholar
  157. Editorial (1975) Calcium, magnesium and diuretics. Br Med J 25:170–171Google Scholar
  158. Eichelbaum M (1976) Drug metabolism in thyroid disease. Clin Pharmacokinetics 1:339–350Google Scholar
  159. Ejvinsson G (1978) Effect of quinidine on plasma concentrations of digoxin. Br Med J 1:279–280PubMedGoogle Scholar
  160. Engel TR, Gonzales ADC (1978) Effects of digitalis on atrial vulnerability. Am J Cardiol 42:570–576PubMedGoogle Scholar
  161. Erbel R, Kraemer R, Kleesiek K, Schweizer P, Pop T, Effert S (1979) Suizidale Digitalisintoxikation : Beziehung zwischen der Digitalis-Serumkonzentration und den elektrokardiographischen Befunden. Z Kardiol 68:590–598PubMedGoogle Scholar
  162. Erdmann E (1975) Bestimmung der Herzglykosidkonzentration im Serum. Internist 16:185–189PubMedGoogle Scholar
  163. Erdmann E (1977) Die Herzglykosidintoxikation. Der informierte Arzt 5:102–112Google Scholar
  164. Erdmann E (1978a) Quantitative Aspekte der spezifischen Bindung von Herzglykosiden an Membranrezeptoren. Habilitationsschrift, Universität München Fortschr Med 96:1758Google Scholar
  165. Erdmann E (1978b) Vergleichende Messungen der Herzglykosidafflnität und der Hemmung der (Na++K+)-ATPase durch Digitoxin, Digoxin, Methyldigoxin, Strophanthin, Procillaridin an isolierten menschlichen Herzmuskelzellmembranen. Arzneimittelforsch 28:531–535Google Scholar
  166. Erdmann E (1980) Überwachung der Digitalistherapie. Med Welt 31:1–3Google Scholar
  167. Erdmann E, Philipp G, Scholz H (1980) Cardiac glycoside receptor, (Na+ +K+)-ATPase activity, and force of contraction in rat heart. Biochem Pharmacol 29:3219–3229PubMedGoogle Scholar
  168. Erdmann E (1981) Influence of cardiac glycosides on their receptor. In: Greef K (ed) Handbook of Experimental Pharmacology, vol 56. Springer, Berlin Heidelberg New York, pp 337–380Google Scholar
  169. Erdmann E, Boite H-D (1979) Zellulärer Mechanismus der Digitaliswirkung. In: Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 131–140Google Scholar
  170. Erdmann E, Bolte H-D (1981) Über den Mechanismus der Herzglykosidwirkung unter besonderer Berücksichtigung des Digitoxins. In: Kochsiek K, Rietbrock N (Hrsg) Digitalistherapie bei Herzinsuffizienz. Urban & Schwarzenberg, München Wien Baltimore, S 66–70Google Scholar
  171. Erdmann E, Brown L (1983) The cardiac-glycoside-receptor-system in the human heart. Eur J Cardiol [Suppl] 4:61–65Google Scholar
  172. Erdmann E, Krawietz W (1976) On the action of triamterene on isolated cell membranes. Arzneimittelforsch 26:1812–1817PubMedGoogle Scholar
  173. Erdmann E, Krawietz W (1977) Increased number of ouabain binding sites in human erythrocyte membranes in chronic hypokalaemia. Acta Biol Med Germ 36:879–883PubMedGoogle Scholar
  174. Erdmann E, Schoner W (1973a) Ouabain-receptor interactions in Na+ +K+)-ATPase preparations from different tissues and species. Determination of kinetic constants and dissociation constants. Biochim Biophys Acta 307:386–398Google Scholar
  175. Erdmann E, Schoner W (1973b) Ouabain-receptor interactions in (Na++K+)-ATPase preparations. II. Effects of cations and nucleotides on rate constants and dissociation constants. Biochim Biophys Acta 330:302–315Google Scholar
  176. Erdmann E, Schoner W (1973c) Ouabain-receptor interactions in (Na+ +K+)-ATPase preparations. III. On the stability of the ouabain receptor against physical treatment, hydrolases, and SH-reagents. Biochim Biophys Acta 330:316–324Google Scholar
  177. Erdmann E, Schoner W (1974a) Eigenschaften des Receptors für Herzglykoside. Klin Wochenschr 52:705–718Google Scholar
  178. Erdmann E, Schoner W (1974b) Die Affinität verschieden strukturierter Herzglykoside sowie DPH und Ro 2-2935 zum Herzglykosidrezeptor. Verh Dtsch Ges Kreislaufforsch 40:309–314Google Scholar
  179. Erdmann E, Werdan K (1981) Untersuchungen zur Chinidin-Digoxin- und Chinidin-Digitoxin Interaktion. In : Kochsiek K, Rietbrock N (Hrsg) Digitalistherapie bei Herzinsuffizienz. Urban & Schwarzenberg, München Wien Baltimore, S 143–146Google Scholar
  180. Erdmann E, Bolte H-D, Lüderitz B (1971) The (Na+ +K+)-ATPase activity of guinea pig heart muscle in potassium deficiency. Arch Biochem Biophys 145:121–125PubMedGoogle Scholar
  181. Erdmann E, Krawietz W, Vogt W (1976a) Zur Bedeutung der Digoxin-Serumkonzentration und deren Beeinflussung. Fortschr Med 94:567–573Google Scholar
  182. Erdmann E, Presek P, Swozil R (1976b) Über den Einfluß von Kalium auf die Bindung von Strophanthin an menschliche Herzmuskelzellmembranen. Klin Wochenschr 54:383–387Google Scholar
  183. Erdmann E, Krawietz W, Poppert D, Krüger R, Arnim Th von, Vogt W, Boite H-D (1977) Zur kardialen Wirkung antikaliuretischer Diuretika — klinische und biochemische Untersuchungen. Klin Wochenschr 55:985–994PubMedGoogle Scholar
  184. Erdmann E, Presek P, Krawietz W (1978) Quantitative und qualitative Messungen der Herzglykosid-Rezeptor-Interaktionen des menschlichen Herzens. Z Kardiol 67:195Google Scholar
  185. Erdmann E, Krawietz W, Koch M (1979) Cardiac glycoside receptors in disease: The number of ouabain binding sites in human erythrocytes is subject to regulation. In :Skou JC, Nørby JG (eds) Na, K-ATPase, structure and kinetics. Academic Press, London, pp 518–524Google Scholar
  186. Erlij D, Mendez R (1964) The modification of digitalis intoxication by excluding adrenergic influences on the heart. J Pharmacol Exp Ther 144:97–104PubMedGoogle Scholar
  187. Evered DC, Chapman C (1971) Plasma digoxin concentrations and digoxin toxicity in hospital patients. Br Heart J 33:540–545PubMedGoogle Scholar
  188. Falch D (1973) The influence of kidney function, body size and age on plasma concentration and urinary excretion of digoxin. Acta Med Scand 194:251–256PubMedGoogle Scholar
  189. Falch D, Teien A (1973) The influence of kidney function on the plasma level and urinary excretion of digoxin. In: Storstein O (ed) Symposium on digitalis. Gyldendal Norsk, Oslo, pp 183–189Google Scholar
  190. Ferrari A, Gregorini L, Ferrari MC, Preti L, Mancia G (1981) Digitalis and baroreceptor reflexes in man. Circulation 63:279–285PubMedGoogle Scholar
  191. Finkelstein FO, Goffinet JA, Hendler ED, Lindenbaum J (1975) Pharmacokinetics of digoxin and digitoxin in patients undergoing hemodialysis. Am J Med 58:525–531PubMedGoogle Scholar
  192. Finotti P, Palatini P (1981) Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase. J Pharmacol Exp Ther 217:784–790PubMedGoogle Scholar
  193. Fisch C, Knoedel SB, Feigenbaum H (1966) Potassium and the monophasic action potential, electrocardiogram, conduction and arrhythmias. Prog Cardiovasc Dis 8:387–405PubMedGoogle Scholar
  194. Flasch H (1975) Die biologische Verfügbarkeit von β-Acetyldigoxin und Digoxin. Klin Wochenschr 53:873–877PubMedGoogle Scholar
  195. Flasch H, Heinz N (1978) Correlation between inhibition of (Na+, K+)-membrane-AT-Pase and positive inotropic activity of cardenolides in isolated papillary muscles of guinea pig. Naunyn Schmiedebergs Arch Pharmacol 304:37–44PubMedGoogle Scholar
  196. Flasch CI, Heinz N (1979) Klinische Untersuchungen mit Digoxin-Tabletten hoher Bio-Verfügbarkeit. Arzneimittelforsch 29:2–12Google Scholar
  197. Flasch H, Asmussen B, Heinz N (1978) Erhöhte Bioverfügbarkeit von Digoxin aus Kieselsäure-Matrix-Zubereitungen. Arzneimittelforsch 28:326–330PubMedGoogle Scholar
  198. Follath F, Roth M (1980) Bedeutung der Serumkonzentrationsbestimmung bei der Diagnose einer Digitalisintoxikation. Cardiology 65:9–12PubMedGoogle Scholar
  199. Fonrose H, Ahlbaum N, Bugatch E, Cohen M, Genovese C, Kelly J (1974) The efficacy of digitalis withdrawal in an institutional aged population. J Am Geriartr Soc22:208–211Google Scholar
  200. Forbush B, Hoffmann JF (1979) Evidence that ouabain binds to the same large polypeptide chain of dimeric Na, K-ATPase that is phasphorylated from Pi. Biochemistry 18:2308–2315PubMedGoogle Scholar
  201. Ford AR, Aronson JK, Grahame-Smith DG, Rose JA (1979a) The characteristics of the binding of 12-x-(3H)-digoxin to the membranes of intact human erythrocytes:Relevance to digoxin therapy. Br J Pharmacol 8:115–124Google Scholar
  202. Ford AR, Aronson JK, Grahame-Smith DG, Carver JG (1979) Changes in cardiac glycoside receptor sites, 86Rb-uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrilation. Br J Clin Pharmacol 8:125–134PubMedGoogle Scholar
  203. Forester W, Lewis RP, Weissler AM, Wilke TA (1974) The onset and magnitude of the contractile response to commonly used digitalis glycosides in normal subjects. Circulation 49:517–521PubMedGoogle Scholar
  204. Fozzard HA, Smith JR (1965) Observations on the localization of tritiated digoxin in myocardial cells by autoradiography and ultramicroscopy. Am Heart J 69:245–252PubMedGoogle Scholar
  205. Franke H, Chowanetz W, Gerhardt K-H, Schramm A (1981) Die Besonderheiten der Herz- und Kreislauferkrankungen im Alter. Internist Prax 21:1–18Google Scholar
  206. Fricke U (1978) Myocardial activity of inhibitions of the Na+-K+-ATPase: Differences in the mode of action and subcellular distribution pattern. Naunyn Schmiedebergs Arch Pharmacol 303:197–204PubMedGoogle Scholar
  207. Froer KL (1975) Therapie des akuten Herzinfarktes und seiner Komplikationen. Wien Med Wochenschr 13:198–201Google Scholar
  208. Gault MH, Charles JD, Sugden DL, Kepkay DC (1977) Hydrolysis of digoxin by acid. J Pharm Pharmacol 29:27–32PubMedGoogle Scholar
  209. Gault H, Kalra J, Ahmed M, Kepkay D, Longerich L, Barrowman J (1981) Influence of gastric pH on digoxin biotransformation. II. Extractable urinary metabolites. Clin Pharmacol Ther 29:181–190PubMedGoogle Scholar
  210. Ghani MF, Smith JR (1974) The effectiveness of magnesium chloride in the treatment of ventricular tachyarrhythmias due to digitalis intoxication. Am Heart J 88:621–626PubMedGoogle Scholar
  211. Ghysel-Burton J, Godfraind T (1975) Stimulation and inhibition by ouabain of the sodium pump in guinea-pig atria. Br J Pharmacol 55:249PPubMedGoogle Scholar
  212. Ghysel-Burton J, Godfraind T (1979) Stimulation and inhibition of the sodium pump by cardioactive steroids in relation to their binding sites and their inotropic effect on guinea-pig isolated atria. Br J Pharmacol 66:175–184PubMedGoogle Scholar
  213. Giardina ACV, Ehlers KH, Morrison JB, Engle MA (1997) Serum digitoxin concentrations in infants and children. Circulation 51:713–717Google Scholar
  214. Gilfrich HJ, Schölmerich P (1975) Digitalisintoxikation. Neuere Gesichtspunkte zur Entstehung und Bewertung. Dtsch Med Wochenschr 100:831–838PubMedGoogle Scholar
  215. Gilfrich HJ, Schölmerich P (1978) Digitalisintoxikation: Komplikationen und Therapie nach Einnahme extremer Dosen. Notfallmedizin 4:266–273Google Scholar
  216. Gilfrich HJ, Schölmerich P (1980) Digitalisintoxikation: Kompikationen und Therapie nach Einnahme extremer Dosen. Klinikarzt 9:9–14Google Scholar
  217. Gilfrich HJ, Okonek S, Manns M, Schuster CJ (1978) Digoxin and digitoxin elimination in man by charcoal hemoperfusion. Klin Wochenschr 56:1179–1183PubMedGoogle Scholar
  218. Gilfrich HJ, Okonek S, Schölmerich P (1979) Ursachen, Erkennung und Behandlung der Glykosidintoxikation. In: Physiologische und pharmakologische Grundlagen der Therapie. Vieweg, BraunschweigGoogle Scholar
  219. Gillis R (1969) Cardiac sympathetic nerve activity; changes induced by ouabain and propranolo. Science 166:508–510PubMedGoogle Scholar
  220. Gillis RA, Pearle DL, Levitt B (1975) Digitalis: A neuroexcitatory drug. Circulation 52:739–742PubMedGoogle Scholar
  221. Gilman H, Grosse-Brockhoff F (1963) Die Therapie mit Herzglykosiden — Richtlinien und Fehlermöglichkeiten. Dtsch Med Wochenschr 88:1–16Google Scholar
  222. Glynn IM (1964) The action of cardiac glycosides on ion movements. Pharmacol Rev 16:381–407PubMedGoogle Scholar
  223. Glynn IM, Karlish SJD (1975) The sodium pump. Annu Rev Physiol 37:13–55PubMedGoogle Scholar
  224. Godfraind T (1975) Cardiac glycoside receptors in the heart. Biochem Pharmacol 24:823–827PubMedGoogle Scholar
  225. Godfraind T, Ghysel-Burton J (1977) Binding sites related to ouabain-induced stimulation or inhibition of the sodium pump. Nature 265:165–166PubMedGoogle Scholar
  226. Godfraind T, Ghysel-Burton J (1979) The inotropic effect of ouabain, ouabagenin and dihydroouabain on guinea-pig atria. Arch Int Pharmacodyn Ther 232:339Google Scholar
  227. Gold H (ed) (1950) Quinidine in disorders of the heart. Hoeber, New York, pp 85–95Google Scholar
  228. Gold H, Modell W, Price L (1932) Combined actions of quinidine and digitalis on the heart. Arch Intern Med 50:766–772Google Scholar
  229. Goldfinger A, Heizer W, Smith T (1973) Absorption of digoxin in patients with malabsorption. In: Storstein O (ed) Symposium on digitalis. Gyldendal, Oslo, pp 224–228Google Scholar
  230. Goldman S, Probst P, Selzer A, Cohn K (1975) Inefficacy of “ therapeutic” serum levels of digoxin in controlling the ventricular rate in atrial fibrillation. Am J Cardiol 35:651–655PubMedGoogle Scholar
  231. Goldschlager AW, Karliner JS, Bronx NY (1967) Ventricular standstill after intravenous diphenylhydantoin. Am Heart J 74:410–412PubMedGoogle Scholar
  232. Goodman DJ, Rossen RM, Cannom DS, Rider AK, Harrison DC (1975a) Effect of digoxin on atrioventricular conduction. Circulation 51:251–256Google Scholar
  233. Goodman DJ, Rossen RM, Inghem R, Rider AK, Harrison DC (1975b) Sinus node function in the denervated human heart. Br Heart J 37:612–618Google Scholar
  234. Grabensee B, Peters U, Risler T (1981) Digitoxin-Elimination durch Plasmaseparation. In: Kochsiek K, Rietbrock N (eds) Digitalistherapie bei Herzinsuffizienz. Urban & Schwarzenberg, München Wien Baltimore, S 157–158Google Scholar
  235. Grahame-Smith DG (1978) Digoxin biovailability problem. In: Dickinson CJ, Marks J (eds) Developments in cardiovascular medicine. MTP, Lancaster, pp 235–254Google Scholar
  236. Greeff K (1974) Bestimmungen des Blutspiegels von Digoxin, Digitoxin und g-Strophan-thin mit Hilfe radioimmunologischer Methoden. Herz/Kreislauf 6:145–149Google Scholar
  237. Greeff H (1977) Zur Pharmakokinetik des g-Strophanthins. Dtsch Med Wochenschr 102:135–139PubMedGoogle Scholar
  238. Greeff K, Schadewaldt H (1981) Introduction and remarks on the history of cardiac glycosides. In: Greeff K (ed) Handbook of experimental pharmacology, vol 56/1:Cardiac glycosides. Springer, Berlin Heidelberg New York, pp 1–12Google Scholar
  239. Greeff K, Wirth K (1981) Pharmacokinetics of strophanthus glycosides. In: Greeff K (ed) Handbook of experimental pharmacology, vol 56: Cardiac glycosides. Springer, Berlin Heidelberg New York, pp 57–86Google Scholar
  240. Greeff K, Strobach H, Verspohl E (1975) Ergebnisse radioimmunologischer Bestimmungen von Digitoxin, Digoxin und g-Strophanthin am Menschen. In: Jahrmärker H (Hrsg) Digitalistherapie, Beiträge zur Pharmakologie. Springer, Berlin Heidelberg New York, S 52–61Google Scholar
  241. Greeff H, Hafner D, Strobach H, Wirth KE (1977) Vergleich der Bioverfügbarkeit bzw. enteralen Resorption des Digoxins, β-Acetyldigoxins und β-Methyldigoxins. Arzneimittelforsch 27:2358–2364PubMedGoogle Scholar
  242. Grissom JH, Sy BG, Duffy JP, Dunea G (1967) Dangerous consequence from use of phenytoin in atrial flutter. Br Med J 4:37Google Scholar
  243. Gross GJ, Warltier DC, Hardman HF, Somani P (1977) The effect of ouabain on untritional circulation and regional myocardial blood flow. Am Heart J 93:487–492PubMedGoogle Scholar
  244. Grosse-Brockhoff F, Hausamen T-U (1975) 200 Jahre Herztherapie mit Digitalis. Dtsch Med Wochenschr 100:1980–1991PubMedGoogle Scholar
  245. Grosse-Brockhoff F, Peters U (1981) Clinical indications and choice of cardiac glycosides, clinical conditions influencing glycoside effects. In: Greeff K (ed) Handbook of experimental pharmacology, vol 56. Cardiac glycosides. Springer, Berlin Heidelberg New York, pp 239–274Google Scholar
  246. Grosse-Brockhoff F, Hengels K, Fritsch W, Grabensee B, Hausamen T (1973) Serumdigoxin und Nierenfunktion. Dtsch Med Wochenschr 98:1547–1551PubMedGoogle Scholar
  247. Grosse-Brockhoff F, Grabensee B, Hausamen T (1977) Glykosidbehandlung in Klinik und Praxis. Verh Dtsch Ges Inn Med 83:57–75PubMedGoogle Scholar
  248. Güllner H-G, Stinson EB, Harrison DC, Kaiman SM (1974) Correlation of serum concentrations with heart concentrations of digoxin in human subjects. Circulation 50:653–655PubMedGoogle Scholar
  249. Güttler K, Klaus W, Land E (1979) Antagonistic effect of triamterene to ouabain toxicity. Arzneimittelforsch 29:623–628PubMedGoogle Scholar
  250. Guz A (1978) The clinical value of digoxin in patients with heart failure and sinus rhythm. In: Dickinson CJ, Marks J (eds) Developments in cardiovascular medicine, MTP, Lancaster, pp 89–101Google Scholar
  251. Guz A, McHaffie D (1978) The use of digitalis glycosides in sinus rhythm. Clin Sci Mol Med 55:417–421PubMedGoogle Scholar
  252. Guzman NT De, Yeh BK (1975) Potassium canrenoate in the treatment of long-term digoxin-induced arrhythmias in conscious dogs. Am J Cardiol 35:413–420Google Scholar
  253. Hass A, Lüllmann H (1972) The absorption rates of some cardiac glycosides and portal blood flow. J Pharmacol 19:366–372Google Scholar
  254. Haasis R, Larbig D (1975) Serumglykosidkonzentration und Digitalisintoxikation. Dtsch Med Wochenschr 100:1768–1773PubMedGoogle Scholar
  255. Haasis R, Larbig D, Klenk KO (1975) Glykosidkonzentration im Serum und Urin bei Herzgesunden nach Gabe von Beta-Methyl-Digoxin. Klin Wochenschr 53:529–533PubMedGoogle Scholar
  256. Haasis R, Larbig D, Stunkat R, Bader H, Seboldt H (1977) Radioimmunologische Bestimmung der Glykosidkonzentration im menschlichen Gewebe. Klin Wochenschr 55:23–30PubMedGoogle Scholar
  257. Haasis R, Mikulla A, Roth W (1980) Klinische Studie zur Interaktion zwischen prajmaliumbitartrat und β-Methyldigoxin. Med Welt 43:3–10Google Scholar
  258. Härtel G, Kyllönen K, Merikallio E, Ojala K, Manninen V, Reissell P (1976) Human serum and myocardium digoxin. Clin Pharmacol Ther 19:153–157PubMedGoogle Scholar
  259. Hagen H (1971) Behandlung von Herzrhythmusstörungen mit Diphenylhydantoin. Dtsch Med Wochenschr 96:380–384PubMedGoogle Scholar
  260. Hager WD, Fenster P, Mayersohn M (1979) Digoxin-quinidine interaction: pharmacokinetic evaluation. N Engl J Med 300:1238PubMedGoogle Scholar
  261. Halkin H, Radomsky M, Millman P, Almog S, Blieden L, Boichis H (1978) Steady state serum concentrations and renal clearance of digoxin in neonates, infants and children. Eur J Clin Pharmacol 13:113–117PubMedGoogle Scholar
  262. Hamer J (1979) The paradox of the lack of the efficacy of digitalis in congestive heart failure with sinus rhythm. Br J Clin Pharmacol 8:109–113PubMedGoogle Scholar
  263. Hansen H-W, Marquort B, Pelz W (1974) Die Indikation für Phenytoin bei Rhythmusstörungen des Herzens. Dtsch Med Wochenschr 99:638–642PubMedGoogle Scholar
  264. Harrigan J, Kangos J, Sikka A, Spisso K, Natarajan N, Rosenfeld D, Leiman S, Korn D (1981) Successful treatment of fetal congestive heart failure secondary to tachycardia. N Engl J Med 304:1527–1529PubMedGoogle Scholar
  265. Harris AS, Kokernot RH (1950) Effects of diphenylhydantoin sodium (Dilantin sodium) and phenobarbital sodium upon ectopic ventricular tachycardia in acute myocardial infarction. Am J Physiol 163:505–516PubMedGoogle Scholar
  266. Hauf G, Bubenheimer E, Lönne E, Roskamm H (1981) Behandlung der Stauungsherzinsuffizienz mit Vasodilatatoren. Dtsch Med Wochenschr 106:1607–1612PubMedGoogle Scholar
  267. Haustein K-O (1977) Absorption and metabolism in man of 16-epi-gitoxin, a new semi1synthetic cardioactive glycosde. Eur J Clin Pharmacol 11:455–458PubMedGoogle Scholar
  268. Hayes C, Butler V, Gersont W (1973) Serum digoxin studies in infants and children. Pediatrics 52:561–578PubMedGoogle Scholar
  269. Heizer WD, Smith TW, Goldfinger SE (1971) Absorption of digoxin in patients with malabsorption syndromes. N Engl J Med 285:257–259PubMedGoogle Scholar
  270. Heifant RH, Scherlag BJ, Damato AN (1967) The electrophysiological properties of diphenylhydantoin sodium as compared to procaine amide in the normal and digitalisintoxicated heart. Circulation 36:108–118Google Scholar
  271. Helfant RH, Seuffert GW, Patton RD, Stein E, Damato AN, Island S (1969) The clinical use of diphenylhydantoin (Dilantin) in the treatment and prevention of cardiac arrhythmias. Am Heart J 77:315–323PubMedGoogle Scholar
  272. Hess T (1976) Herzinsuffizienz und Digitalisbehandlung. Schweiz Rundschau Med 65:6–14Google Scholar
  273. Hess T (1981) Unterdosierung und Überdosierung von Digitalis. Schweiz Med Wochenschr 11:455–460Google Scholar
  274. Hess T, Stucki P (1975) Mesenterialinfarkt bei Digitalisintoxikation. Schweiz Med Wochenschr 105:1237–1240PubMedGoogle Scholar
  275. Hess T, Dubach HU, Scholtysik G, Riesen W (1982) Suicidal digoxin poisoning: Conventional treatment and antibody therapy. Klin Wochenschr 60:401–405PubMedGoogle Scholar
  276. Hirschberg R, Schaefer K, Herrath D von, Kreutz G, Kewitz H (1981) Digoxin-quinidine interaction in patients with renal failure. Klin Wochenschr 59:521–522PubMedGoogle Scholar
  277. Hobson JD, Zettner A (1973) Digoxin serum half-life following suicidal digoxin poisoning. JAMA 223:147–149PubMedGoogle Scholar
  278. Hoch JH (1961) A survey of cardiac glycoside and genius. University of South Carolina Press, South CarolinaGoogle Scholar
  279. Hochrein H, Lehmann H-U, Helwing H-P (1975) EKG-Veränderungen bei Koronarinsuffizienz und unter dem Einfluß von Digitalis. Klinikarzt 4:403–407Google Scholar
  280. Hoeschen RJ, Cuddy TE (1975) Dose-response relation between therapeutic levels of serum digoxin and systolic time intervals. Am J Cardiol 35:469–472PubMedGoogle Scholar
  281. Hoffman B, Bigger J (1980) Digitalis and allied cardiac glycosides. In: Goodmann K, Gilman A (eds) The pharmacological basis of therapeutics. MacMillan, New York, pp 729–760Google Scholar
  282. Hoffman JF (1966) The red cell membrane and the transport of sodium and potassium. Am J Med 41:666–680PubMedGoogle Scholar
  283. Hokin IE (1974) Purification and properties of the (sodium+potassium)-activated adenosinetriphosphatase and reconstitution of sodium transport. Ann NY Acad Sci 242:12–23PubMedGoogle Scholar
  284. Holt DW, Goulding R (1975) Magnesium depletion and digoxin toxicity. Br Med J 15:627–628Google Scholar
  285. Honerjäger P, Schäfer-Körting M, Reiter M (1981) Involvement of cyclic AMP in the direct inotropic action of amrinone. Biochemical and functional evidence. Naunyn Schmiedebergs Arch Pharmacol 31:112–120Google Scholar
  286. Horvath I, Kiraly C, Suerb J (1949) Action of cardiac glycosides on the polymerisation of actin. Nature 165:792Google Scholar
  287. Horwitz LD, Atkins JM, Saito M (1977) Effect of digitalis on left ventricular function in exercising dogs. Circ Res 41:744–750PubMedGoogle Scholar
  288. Hsieh Y-Y, Goldberg LI, Arnsdorf MF (1978) Cardiac glycosides, theophylline, morphine, and vasodilators. In: Hurst J (ed) The heart, arteries and veins. McGraw-Hill, New York, pp 1965–1980Google Scholar
  289. Huffman DH (1975) Relationship between digoxin concentrations in serum and saliva. Clin Pharmacol Ther 17:310–312PubMedGoogle Scholar
  290. Huffman DH, Azarnoff DL (1975) Pharmakologie und praktische Therapie. Die Anwendung von Digitalisglykosiden. Internist 16:29–35Google Scholar
  291. Hull SM, Mackintosh A (1977) Discontinuation of maintenance digoxin therapy in general practice. Lancet 11:1054Google Scholar
  292. Hurst JW, Paulk EA, Proctor HD, Schlant RC (1964) Management of patients with atrial fibrillation. Am J Med 37:728–741PubMedGoogle Scholar
  293. Hutcheon DE (1975) Cardiovascular drug interactions. J Clin Pharmacol 15:129–134PubMedGoogle Scholar
  294. Iisalo E, Dahl M, Sundqvist H (1973) Serum digoxin in adults and children. Int J Clin Pharmacol 7:219–222PubMedGoogle Scholar
  295. Ingelfinger JA, Goldman P (1976) The serum digitialis concentration — does it diagnose digitalis toxicity? N Engl J Med 294:867–870PubMedGoogle Scholar
  296. Jacobsen AL (1968) Effect of ouabain on the ATPase of cardiac myosin B at high ionic strength. Circ Res 22:625–632Google Scholar
  297. Jahrmärker H (1973) Zur prophylaktischen Glykosidanwendung. Internist 14:306–312PubMedGoogle Scholar
  298. Jelliffe RW, Brooker G (1974) A nomogram for digoxin therapy. Am J Med 57:63–68PubMedGoogle Scholar
  299. Jogestrand T, Sundqvist K (1981) Skeletal muscle digoxin concentration and its relation to serum digoxin concentration and cardiac effect in healthy man. Eur J Clin Pharmacol 19(2):89–95PubMedGoogle Scholar
  300. Jogestrand T, Ericsson F, Sundqvist K (1981) Skeletal muscle digoxin concentration during digitalization and during withdrawal of digoxin treatment. Eur J Clin Pharmacol 19:97–105PubMedGoogle Scholar
  301. Johnson LW, Dickstein RA, Fruehan CTh, Kane P, Potts JL, Smulyan H, Webb WR, Eich RH (1976) Prophylactic digitalization for coronary artery bypass surgery. Circulation 53:819–822PubMedGoogle Scholar
  302. Johnston GD, McDevitt DG (1978) Digoxin compliance in patients from general practice. Br J Clin Pharmacol 6:339–343PubMedGoogle Scholar
  303. Johnston GD, McDevitt DG (1979) Is maintenance digoxin necessary in patients with sinus rhythm? Lancet 1:567–570PubMedGoogle Scholar
  304. Jørgensen PL (1975) Isolation and characterization of the components of the sodium pump. Q Rev Biophys 7:239–274Google Scholar
  305. Jork K, Kuschinsky G, Reuter H (1967) Der Einfluß der extracellulären Calciumkonzentration auf die Wirkung von Noradrenalin, β-Adrenolytica und Chinidin an isolierten Meerschweinchenvorhöfen. Naunyn Schmiedebergs Arch Pharmacol 258:59–68Google Scholar
  306. Juhl RP, Summers RW, Guillory JK, Blaug SM, Cheng FH, Brown DD (1976) Effect of sulfasalazine on digoxin bioavailability. Clin Pharmacol Ther 20:387–394PubMedGoogle Scholar
  307. Jusko WJ, Szefler St, Godfarb A (1974) Pharmacokinetics design of digoxin dosage regimens in relativ to renal function. J Clin Pharmacol 14:525–535PubMedGoogle Scholar
  308. Karjalainen J, Ojala K, Reissell P (1974) Non-equivalent digoxin tablets. Ann Clin Res 6:132–136PubMedGoogle Scholar
  309. Karliner JS (1967) Intravenous diphenylhydantoin sodium (Dilantin) in cardiac arrhythmias. Dis Chest 51:256–269PubMedGoogle Scholar
  310. Kassebaum D (1963) Electrophysiological effects of strophanthin in the heart. J Pharmacol Exp Ther 140:329–334Google Scholar
  311. Katz AM (1978) A new inotropic drug: Its promise and a caution. N Engl J Med 299:1409–1410PubMedGoogle Scholar
  312. Kaufmann G, Hauser K (1968) Erfahrungen mit Diphenylhydantoin (Antisacer) in der Behandlung kardialer Rhythmusstörungen. Schweiz Med Wochenschr 98:1223–1226PubMedGoogle Scholar
  313. Kaufmann G, Weber-Eggenberger S (1970) Hämodynamische Veränderungen durch Diphenylhydantoin bei digitalisierten Herzkranken. Schweiz Med Wochenschr 100:2164–2168PubMedGoogle Scholar
  314. Kearin M, Kelly JG, O’Malley K (1980) Digoxin “receptors” in neonates: An explanation of less sensitivity to digoxin than in adults. Clin Pharmacol Ther 28:346–349PubMedGoogle Scholar
  315. Keeran M (1967) Cardiac arrest following intravenous administration of diphenylhydantoin. OSMA J 60:334–335Google Scholar
  316. Keller F, Blumenthal HP, Maertin K, Rietbrock N (1977) Overall pharmacokinetics during prolonged treatment of healthy volunteers with digoxin and β-methaldigoxin. Eur J Clin Pharmacol 12:387–392PubMedGoogle Scholar
  317. Kerenyi Th, Gleicher N, Meiler J, Brown E, Steinfeld L, Chitkara U, Raucher H (1980) Transplacental cardioversion of intrauterine supraventricular tachycardia with digitalis. Lancet 1:393–394Google Scholar
  318. Kim YI, Noble RJ, Zipes DP (1975) Dissociation of the ionotropic effect of digitalis from its effect on atrioventricular conduction. Am J Cardiol 36:459–467PubMedGoogle Scholar
  319. Klaassen CD (1974) Stimulation of the development of the hepatic excretory mechanism for ouabain in newborn rats with microsomal enzyme inducers. J Pharmacol Exp Ther 191:212–218PubMedGoogle Scholar
  320. Kleiman JH, Ingels NB, Daughters G, Stinson EB, Alderman EL, Goldman RH (1978) Left ventricular dynamics during long-term digoxin treatment in patients with stable coronary artery disease. Am J Cardiol 41:937–942PubMedGoogle Scholar
  321. Klein M, Nejad NS, Hagemeijer F, Barr I (1971) Correlation of the electrical and mechanical changes in the dog heart during progressive digitalization. Circ Res 29:635–645PubMedGoogle Scholar
  322. Klein MD, Lown B, Barr I, Hagemeijer F, Garrison H, Axelrod P (1974) Comparison of serum digoxin level measurement with acetyl strophanthidin tolerance testing. Circulation 44:1053–1062Google Scholar
  323. Klein H, Lang R, Segni E, Kaplinsky E (1980) Verpamil-digoxin interaction. N Engl J Med 303:160PubMedGoogle Scholar
  324. Kochsiek K (1980) Probleme der Digoxintherapie. Dtsch Med Wochenschr 105:539–541PubMedGoogle Scholar
  325. Kochsiek K, Larbig D, Haasis R (1977) Klinik und Therapie der Digitalisintoxikation. Verh Dtsch Ges Inn Med 83:199–115Google Scholar
  326. Koch-Weser J (1979) Drug-induced dysrhythmias in man. Pharmacol Ther [B] 5:125–131Google Scholar
  327. Kokenge F, Zwieten P van (1971) A diminished response to digoxin in isolated heart muscle as a result of fever. Klin Wochenschr 49:1236–1237PubMedGoogle Scholar
  328. Kolenda KD, Jost St, Kokenge F (1978) Digoxin oder Digitoxin? Ein Beitrag zur rationellen Therapie mit Herzglykosiden. Therapiewoche 28:8726–8730Google Scholar
  329. Koup JR (1980) Distribution of digoxin in hyperthyroid patients. Int J Clin Pharmacol 18:234–235Google Scholar
  330. Koup JR, Jusko WJ Elwood CM, Kohli RK (1975) Digoxin pharmacokinetics: Role of renal failure. Clin Pharmacol Ther 18:9–21PubMedGoogle Scholar
  331. Krakauer R, Petersen B (1979) The effects of discontinuing maintenance digoxin therapy; a study of elderly cardiac patients in sinus rhythm. Dan Med Bull 26:10–13PubMedGoogle Scholar
  332. Kramer P (1977) Digitalis pharmacokinetics and therapy with respect to impaired renal function. Klin Wochenschr 55:1–11PubMedGoogle Scholar
  333. Kramer P, Scheler F (1972) Renale Eliminationskinetik verschiedener Herzglykoside. Dtsch Med Wochenschr 97:1485–1490PubMedGoogle Scholar
  334. Kramer P, Scheler F (1980) Digitalis und Urämie. Dtsch Med Wochenschr 105:848–850PubMedGoogle Scholar
  335. Kramer P, Quellhorst E, Horenkamp G, Scheler F (1972) Dialysance and prozentuale Elimination verschiedener Herzglykoside während der Hämo- und Peritomaldialyse. Klin Wochenschr 50:609–613PubMedGoogle Scholar
  336. Kramer P, Köthe E, Saul J, Scheler F (1974) Uraemic and normal plasma protein binding of various cardiac glycosides under „in vivo“ conditions. Eur J Clin Invest 4:53–58PubMedGoogle Scholar
  337. Kramer P, Langescheid C, Saul J, Heurer E, Löffler G, Köthe E, Mclntosh C, Scheler F (1977) Plasma digoxin levels in anuric patients and normal subjects taking digitoxin. Klin Wochenschr 55:245–246PubMedGoogle Scholar
  338. Kramer P, Stroh E, Matthaei D, Teiwes F, Scheler F (1978) Increased digitalis tolerance in uraemie patients. In: Bodem G, Dentier H (eds) Cardiac glycosides. Springer, Berlin Heidelberg New York, pp 304–313Google Scholar
  339. Kraupp O (1980) Pharmakodynamische Beeinflussung der Rhythmik, Dynamik und Durchblutung des Herzens. In: Forth W, Nenschler D, Rummel W (Hrsg) Allgemeine und spezielle Pharmakologie und Toxikologie. Wissenschaftsverlag, Bibliographisches Institut, Mannheim Wien Zürich, S 165–225Google Scholar
  340. Krebs R (1976) Modifizierende Faktoren in der Therapie mit Herzglykosiden. Med Klin 71:1759–1770PubMedGoogle Scholar
  341. Krebs R, Kersting F (1979) The effect of barbiturates on the myocardium and its reversibility. Prog Pharmacol 2:1–16Google Scholar
  342. Ku DD, Akera T, Brody TM, Weaver LC (1977) Chronic digoxin treatment on canine myocardial Na+, K+-ATPase. Naunyn Schmiedebergs Arch Pharmacol 301:39–47PubMedGoogle Scholar
  343. Kübier W (1981) Digitalisglykoside vor aortokoronarer Bypass-Operation? Dtsch Med Wochenschr 106:555Google Scholar
  344. Kuhlmann J (1981) Digitalisierung bei zytostatischer Therapie. Dtsch. Med Wochenschr 106:468–470Google Scholar
  345. Kuhlmann J, Abshagen U, Rietbrock N (1974) Pharmacokinetics and metabolism of digoxigenin-mono-digitoxoside in man. Eur J Clin Pharmacol 7:87–94PubMedGoogle Scholar
  346. Kuhlmann J, Kötter V, Leitner E v, Arbeiter G, Schröder R, Rietbrock N (1975) Concentration of digoxin, methyldigoxin, digitoxin and ouabain in the myocardium of the dog following coronary occlusion. Naunyn Schmiedebergs Arch Pharmacol 287:399–411PubMedGoogle Scholar
  347. Kuhlmann J, Erdmann E, Rietbrock N (1979) Distribution of cardiac glycosides in heart and brain of dogs and their affinity to the (Na+ +K+)-ATPase. Nauny Schmiedebergs Arch Pharmacol 307:65–71Google Scholar
  348. Kumar R, Yankoponlos N A, Abelmann WH (1973) Ouabain-induced hypertension in a patient with decompensated hypertensive heart disease. Chest 63:105–107PubMedGoogle Scholar
  349. Kuschinsky K (1968) Bestimmung der Eiweißbindung verschiedener Herzglykoside mittels Sephadex-Gelfiltration. Naunxyn Schmiedebergs Arch Pharmacol 29:394–399Google Scholar
  350. Lahiri K, Ertel N (1972) Mechanism of diphenylhydantoin (DPH) induced decrease in serum digoxin (DG) levels. Clin Res 20:410–414Google Scholar
  351. Lang E (1978) „Gibt es ein Altersherz“? Musik und Medizin 9:29–38Google Scholar
  352. Langer GA (1972) Effects of digitalis on myocardial ionic exchange. Circulation 46:180–187PubMedGoogle Scholar
  353. Langer GA (1977) Relationship between myocardial contractility and the effect of digitalison ionic exchange. Fed Proc 36:2231–2234PubMedGoogle Scholar
  354. Larbig D, Kochsiek K, Schrader Chr (1972) Klinische Aspekte der radioimmunchemischen Bestimmung der Serum-Digoxinkonzentration. Dtsch Med Wochenschr 97:139–145PubMedGoogle Scholar
  355. Larbig D, Haasis R, Kochsiek K (1978) Die Glykosidkonzentration und ihre klinische Bedeutung. In: Forum Cardiologium 15. Mannheimer Morgen, MannheimGoogle Scholar
  356. Larno S par, Witchitz S, Giudicelli JF, Boissier JR (1975) Association dephénylhydan-toine-adrénolytiques β et intoxication digitalique. Cœur Med Interne 14:459–463PubMedGoogle Scholar
  357. Lasagna L (1976) How useful are serum digitalis measurements? N Engl J Med 294:898–899PubMedGoogle Scholar
  358. Laube H (1981) Gynäkomastie. Dtsch Aertzebl 6:217–222Google Scholar
  359. Lauf PK (1975) Antigen-antibody reactions and cation transport in biomembranes: Immunophysiological aspects. Biochem Biophys Acta 415:173–229PubMedGoogle Scholar
  360. Lauterbach F (1981) Intestinal absorption and secretion of cardiac glycosides. In: Greeff K (ed) Handbook of experimental pharmacology, vol 56: Cardiac glycosides. Springer, Berlin Heidelberg New York, pp 104–139Google Scholar
  361. Leahey EB, Giardina E-GV, Reiffei JA, Bigger JT (1979a) Serum digoxin concentrations during quinidine and procainamide administration. Circ Res 59:11–101Google Scholar
  362. Leahey EB, Reiffei JA, Heissenbuttel RH, Drusin RE, Lovejoy WP, Bigger JT (1979b) Enhanced cardiac effect of digoxin during quinidine treatment. Arch Intern Med 139:519–521Google Scholar
  363. Lee ChO, Kang DH, Sokol JH, Lee KS (1980) Relation between intracellular Na ion activity and tension of sheep cardiac Purkinje fibers exposed to dihydroouabain. Biophys J 29:315–330PubMedGoogle Scholar
  364. Lee KS, Klaus W (1971) The subcellular basis for the mechanism of inotropic action of cardiac glycosides. Pharmacol Rev 23:193–261PubMedGoogle Scholar
  365. Lehmann H-U, Witt E, Temmen L, Hochrein H (1978) Lebensbedrohliche Digitalisintoxikationen mit und ohne saluretische Zusatztherapie. Dtsch Med Wochenschr 40:1566–1571Google Scholar
  366. Leopold G, Pabst J, Ungethüm W, Schad W, Meub R (1979) Bioverfügbarkeit von Digitoxin. In : Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 35–51Google Scholar
  367. Levey M, Kewitz H, Altwein W, Hillebrand J, Eliakim M (1980) Hospital ademissions due to adverse drug reactions: A comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol 17:25–31Google Scholar
  368. Levine B, Franciosa J, Cohn J (1980) Acute and long term response to an oral convertingenzyme inhibitor, captopril, in congestive heart failure. Circulation 62:35–41PubMedGoogle Scholar
  369. Lichey J, Havestatt Ch, Weinmann J, Hasford J, Rietbrock N (1978) Human myocardium and plasma digoxin concentration in patients on long-term digoxin therapy. Int J Clin Pharmacol 16:460–462Google Scholar
  370. Lin MH, Romsos DR, Akera T, Leveille G A (1978) Na+, K+-ATPase Enzyme units in skeletal muscle from lean and obese mice. Biochem Biophys Res Commun 80:398–404PubMedGoogle Scholar
  371. Lindenbaum J, Mellow MH, Blackstone MO, Butler VP (1971) Variation in biologic abailability of digoxin from four preparations. N Engl J Med 285:1344–1347PubMedGoogle Scholar
  372. Lindenbaum J, Maulitz RM, Butler VP (1976) Inhibition of digoxin absorption by neomycin. Gastroenterology 71:399–404PubMedGoogle Scholar
  373. Lindenbaum J, Rund D, Butler V, Tse-Eng D, Saha J (1981) Inactivation of digoxin by the gut flora : Reversal by antibiotic therapy. N Engl J Med 305:789–794PubMedGoogle Scholar
  374. Lindenmayer GE, Schwartz A, Thopson HK (1974) A kinetic description for sodium and potassium effects on (Na+ + K+)-adenosine triphosphatase : A model for a twononequivalent site potassium activation and an analysis of multiequivalent site models for sodium activation. J Physiol 236:1–28PubMedGoogle Scholar
  375. Liverpool Therapeutics Group (1978) Use of digitalis in general practice. Br Med J 2:673–675Google Scholar
  376. Lown B, Kleiger R, Williams J (1965) Cardioversion and digitalis drugs: Changed threshold to electric shock in digitalized animals. Circ Res 17:519–531PubMedGoogle Scholar
  377. Lowry K, Nagarj R, Pitts B, Askari A (1973) Effects of quinidine on some reactions and ion transport catalyzed by the Na, K-ATPase complex. Biochem Pharmacol 22:1369–1377PubMedGoogle Scholar
  378. Luchi RJ, Gruber JW (1968) Unusually large digitalis requirements. Am J Med 45:322–328PubMedGoogle Scholar
  379. Luckey H (1957) Selection of digitalis preparations and their proper administration. Am J Med 17:21–274Google Scholar
  380. Lüderitz B (1981) Einführung: Ventrikuläre Herzrhythmusstörungen. Pathophysiologie, Klinik, Therapie. In: Lüderitz B (Hrsg) Ventrikuläre Herzrhythmusstörungen. Springer, Berlin Heidelberg New York, S 1–25Google Scholar
  381. Lüderitz B, Naumann d’Alnoncourt C, Thomas E, Steinbeck G (1975) Elektrophysiologische Untersuchungen über kardiale Wirkungen von Diuretika. Verh Dtsch Ges Kreislaufforsch 41:305–310PubMedGoogle Scholar
  382. Lüderitz B, Naumann d’Alnoncourt C, Steinbeck G (1977) Effects on antikaliuretic agents on cardiac electrophysiology — measurements in papillary heart muscle and in Purkinje fibers. Klin Wochenschr 55:423–427PubMedGoogle Scholar
  383. Lüllmann H, Peters T (1974) Cardiac glycosides and contractility. Adv Cardiol 12:174–182PubMedGoogle Scholar
  384. Lüllmann H, Weber R (1968) Über die Wirkung von Phenytoin auf Digitalis-bedingte Arrhythmien. Aerztl Forsch 22:49–55PubMedGoogle Scholar
  385. Lüllmann H, Peters T, Seiler K-U (1971) Über die Verteilung und Biotransformation verschiedener Herzglykoside. Dtsch Med Wochenschr 96:1018–1021PubMedGoogle Scholar
  386. Lüllmann H, Peters T, Ziegler A (1979) Kinetic events determining the effects of cardiac glycosides. TIPS, pp 012–106Google Scholar
  387. Lukas D (1973a) Binding of digitoxin, digoxin, their genius and related digitoxosides to human plasma protein. In: Storstein O (ed) Symposium on digitalis. Gyldendal Norsk, Oslo, pp 31–48Google Scholar
  388. Lukas D (1973b) The pharmakokinetics and metabolism of digitoxin in man. In: Storstein O (ed) Symposium on digitalis. Gyldendal Norsk, Oslo, pp 84–102Google Scholar
  389. Lukas D (1973c) The role of the liver in the chemical transformation of digitoxin. In: Storstein O (ed) Symposium on digitalis. Gyldendal Norsk, Oslo, pp 192–199Google Scholar
  390. Macdonald Hull S (1977) Discontinuation of maitenance digoxin therapy in general practice. Lancet 2:1054–1055Google Scholar
  391. Mahler F, Karliner JS, O’Raurke RA (1974) Effects of chronic digoxin in the normal conscious dog. Circulation 50:720–727PubMedGoogle Scholar
  392. Mahon WA (1980) Cardiac glykosides and drugs used in arrhythmias. In: Dukes M (ed) Meyler’s side effects of drugs. Excerpta Medica, Amsterdam Oxford Princeton, pp 280–294Google Scholar
  393. Malcolm A, Coltart J (1977) Relation between concentrations of digoxin in the myocardium and in the plasma. Br Heart J 39:935–938PubMedGoogle Scholar
  394. Manninen V, Apajalakti A, Melin J (1973) Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet 1:398–400PubMedGoogle Scholar
  395. Marcus FI (1973a) Metabolism of digoxin in normal man and factors influencing the body distribution. In: Storstein O (ed) Symposium on digitalis. Gyldendal Norsk, Oslo, pp 112–125Google Scholar
  396. Marcus FI (1973b) The role of the liver in the transformation and excretion of digoxin. In: Storstein O (ed) Symposium on digitalis. Gyldendal Norsk, Oslo, pp 200–208Google Scholar
  397. Marcus FI (1975) Digitalis pharmacokinetics and metabolism. Am J Med 58:452–459PubMedGoogle Scholar
  398. Marcus FI (1980) Editorial: Use of digitalis in acute myocardial infarction. Circulation 62:17–19PubMedGoogle Scholar
  399. Marcus FI, Ryan JN, Stafford MG (1975) The reactivity of derivates of digoxin and digitoxin as measured by the Na — K-ATPase displacement assay and by radioimmunoassay. J Lab Clin Med 85:610–620PubMedGoogle Scholar
  400. Mårdh S (1973) A simple enzymatic assay of cardiac glycosides and its application to analysis of glycoside levels in plasma. Clin Chim Acta 44:165–172PubMedGoogle Scholar
  401. Margolis JR, Strauss HC, Miller HC, Gilbert M, Wallace AG (1975) Digitalis and the sick sinus syndrome clinical and electrophysiologic documentation of a severe toxic effect on sinus node function. Circulation 52:162–169PubMedGoogle Scholar
  402. Maroko PR, Ribeiro LGT, Kloner RA, Hale SL, Ingwall JS (1978) Transport of ATP by liposomes into the ischemic myocardium. Circulation 57:11–58Google Scholar
  403. Mason DT (1974) Digitalis pharmacology and therapeutics: Recent advances. Ann Intern Med 80:520–530PubMedGoogle Scholar
  404. Mason D T (1978) Symposium perspective. Am J Med 65:101–105PubMedGoogle Scholar
  405. Mason DT, Awan NA (1979) Recent advances in digitalis research. Am J Cardiol 43:1056–1059PubMedGoogle Scholar
  406. Mason DT, Braunwald E (1964) Studies on digitalis. X. Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients in heart failure. J Clin Invest 43:532–543PubMedGoogle Scholar
  407. Mason DT, Forester JM (1981) Side effects and intoxication of cardiac glycosides: manifestations and treatment. In : Greeff K (ed) Handbook of experimental pharmacology, vol 56/II : Cardiac glycosides. Springer, Berlin Heidelberg New York, pp 275–297Google Scholar
  408. Mathur PN, Powles P, Pugsley StO, McEwan MP, Campbell M (1981) Effect of digoxin on right ventricular function in severe chronic airflow obstruction. Ann Intern Med 95:283–288PubMedGoogle Scholar
  409. Mayahara H, Ogawa K (1980) Ultracytochemical localization of ouabain-sensitive, potas-sium-dependent p-nitrophenyl-phosphatase activity in the rat kidney. Acta Histochem Cytochem 13:90–102Google Scholar
  410. Mayahara H, Fujimoto K, Anso T, Ogawa K (1980) A new one-step method for the cytochemical localization of ouabain-sensitive, potassium-dependent p-nitrophenyl-phosphatase activity. Histochemistry 67:125–138PubMedGoogle Scholar
  411. McCall D (1979) Cation exchange and glycoside binding in cultured rat heart cells. Am J Physiol 236:C87-C95PubMedGoogle Scholar
  412. McHaffie S, Purcell H, Mitchell-Heggs P, Guz A (1978) The clinical value of digoxin in patients with heart failure and sinus rhythm. Q J Med 47:401–419PubMedGoogle Scholar
  413. McMichael J, Sharpey-Schafer EP (1944) The action of intravenous digoxin in man. QJ Med 52:123–135Google Scholar
  414. Medenica R, Hatam K, Hatam V, Girard J, Junet R (1972) Digitoxin induced thrombocytopenia. Int Arch Allergy Appl Immunol 43:1–9PubMedGoogle Scholar
  415. Meyer J (1970) Zur Frage der Digitalisanwendung vor, während und nach Operationen. Anaesthesist 19:365–369PubMedGoogle Scholar
  416. Michael LH, Schwartz A, Wallick ET (1979) Nature of the transport adenosine triphos-phatase-digitalis complex: XIV. Inotropy and cardiac glycoside interaction with Na+, K+ -ATPase of isolated cat papillary muscle. Mol Pharmacol 16:135–146PubMedGoogle Scholar
  417. Michel D (1977) Das sogenannte Altersherz und seine Behandlung. Therapiewoche 27:5425–5433Google Scholar
  418. Michel D (1981) Digitalis-Therapie im Alter. Folge 2: Risiken, Glykosid-Präparate. Fortschr Med 99:669–675PubMedGoogle Scholar
  419. Miller RR, Vismara LA, Williams DO, Amsterdam EA, Mason DT (1976) Pharmacological mechanisms for left ventricular unloading in clinical congestive heart failure. Differential effects of nitroprusside, phentolamine, and nitroglycerin on cardiac function and peripheral circulation. Circulation 39:127–133Google Scholar
  420. Moe G, Farah A (1975) Digitalis and allied cardiac glycosides. In: Goodman L, Gilman A (eds) The pharmacological basis of therapeutics. MacMillan, New York, pp 653–682Google Scholar
  421. Morrison J, Coromilas J, Robbins J, Ong L, Eisenberg S, Stechel R, Zema M, Reiser P, Scherr L (1980) Digitalis and myocardial infarction in man. Circulation 62:8–16PubMedGoogle Scholar
  422. Morrow D, Townley N (1964) Anaesthesia and digitalis toxicity: an experiment study. Anesth Analg (Paris) 43:510–519Google Scholar
  423. Morselli P (1976) Clinical pharmacokinetics in neonates. Clin Pharmacokinetics 1:81–98Google Scholar
  424. Moss A, Davies H, Conrad D, De Camilla C, Odoroff C (1980) Digitalis associated cardiac mortality after myocardial infarktion. Circulation 64:1150–1156Google Scholar
  425. Moysey JO, Jaggarao NSV, Grundy EN, Chamberlain DA (1981) Amiodarone increases plasma digoxin concentrations. Br Med J 282:272Google Scholar
  426. Mudge G, Welt L (1975) Agents affecting volume and composition of body fluids. In:Godman LS, Gilman A (eds) The Pharmacological basis of therapeutics. MacMillan, New York, pp 753–797Google Scholar
  427. Müller H, Bräuer H, Förster G, Reinhardt F (1978) Digoxinbestimmung mit Enzymimmunoassay und Radioimmunoassay. Klin Wochenschr 56:493–496PubMedGoogle Scholar
  428. Murthy RV, Kidwai AM, Daniel EE (1974) Dissociation of contractile effect and binding and inhibition on Na+ — K+-adenosine triphosphatase by cardiac glycosides in rabbit myometrium. J Pharmacol Exp Ther 188:575–581PubMedGoogle Scholar
  429. Neff MS, Mendelssohn S, Kim KE, Banach S, Swartz C, Seller RH (1972) Magnesium sulfate in digitalis toxicity. Am J Cardiol 29:377–382PubMedGoogle Scholar
  430. Nelson GR, Sonnenblick EH, Kirk ES (1975) Mechanism of the salutory effects of digitalis on myocardial ischemia with failure. Clin Res 23:382AGoogle Scholar
  431. Neuvonen PJ, Elfving SM, Elonen E (1978) Reduction of absorption of digoxin, phenytoin and aspirin by activated chracoal in man. Eur J Clin Pharmacol 13:213–318PubMedGoogle Scholar
  432. Nickerson M, Collier B (1975) Drugs inhibiting adrenergic nerves and structures innervated by them. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics. MacMillan, New York, pp 533–564Google Scholar
  433. Nieder R (1977) Dosierung von β-Acetyldigoxin für Kinder. Kinderarzt 3:1–12Google Scholar
  434. Nishimura H, Taninura T (1976) Clinical aspects of teratogenity of drugs. Excerpta Medica, Amsterdam Oxford, pp 124–168Google Scholar
  435. Noble D (1980) Mechanism of action of therapeutic levels of cardiac glycosides. Cardiovasc Res 14:495–514PubMedGoogle Scholar
  436. Nola G, Pope S, Harrison D (1970) Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J 79:499–507PubMedGoogle Scholar
  437. Ochs H, Bodem G (1981) Alternation zur Digitalistherapie? Dtsch Med Wochenschr 106:583–586PubMedGoogle Scholar
  438. Ochs H, Bodem G, Dengler HJ (1974) Die biologische Verfügbarkeit von Digoxin aus Kombinationspräparaten. Klin Wochenschr 52:637–639PubMedGoogle Scholar
  439. Ochs H, Bodem G, Shäfer PK, Kodrat G, Dengler HJ (1975) Absorption of digoxin from the distal parts of the intestine in man. Eur J Clin Pharmacol 9:95–97PubMedGoogle Scholar
  440. Ochs HR, Otten H, Bodem G (1979) Digoxin-induzierte Veränderungen des Belastungs-EKG in Relation zur Digoxinplasmakonzentration. Klin Wochenschr 57:161–168PubMedGoogle Scholar
  441. Ochs HR, Greenblatt DJ, Harmatz JS, Bodem G, Dengler HJ (1981) Clinical implications of serum digoxin concentrations. Klin Wochenschr 59:501–507PubMedGoogle Scholar
  442. Ohnhaus EE (1983) Dosierung von Herzglykosiden. In: Erdmann E (Hrsg) Therapie mit Herzglykosiden. Springer, Berlin Heidelberg New York, S 40–47Google Scholar
  443. Ohnhaus EE, Spring P, Dettli L (1972) Protein binding of digoxin in human serum. Eur J Clin Pharmacol 5:34–36Google Scholar
  444. Ohnhaus EE, Spring P, Dettli L (1974) Eliminationskinetik und Dosierung von Digoxin bei Patienten mit Niereninsuffizienz. Dtsch Med Wochenschr 99:1797–1803PubMedGoogle Scholar
  445. Ohnhaus EE, Vozeh S, Nuesch E (1979) Absorption of digoxin in severe right heart failure. Eur J Clin Pharmacol 15:115–120PubMedGoogle Scholar
  446. Okarma TB, Tramell P, Kaiman SM (1972) The surface interaction between digoxin and cultured heart cells. J Pharmacol Exp Ther 185:559–576Google Scholar
  447. Okita GT (1975) Dissociation of the positive inotropic effects from the cardiotoxicity effects of digitalis. Proc West Pharmacol Soc 18:14–19PubMedGoogle Scholar
  448. Okita GT, Richardson F, Roth-Schechter BF (1973) Dissociation of the positive inotropic action of digitalis from inhibition of sodium- and potassium-activated adenosine triphosphatase. J Pharmacol Exp Ther 185:1–11PubMedGoogle Scholar
  449. Oliver GC, Parker M, Brasfield D (1968) The measurement of digitoxin in human serum by radioimmunoassay. J Clin Invest 47:1035–1041PubMedGoogle Scholar
  450. Oliver G, Taxman R, Frederickson R (1973) Influence of congestive heart failure on digoxin blood levels. In: Storstein O (ed) Symposium on digitalis. Gyldendal Norsk, Oslo, pp 336–347Google Scholar
  451. Olson RE, Ellenbogen E, Iyengar R (1961) Cardiac myosin and congestive heart failure in the dog. Circulation 24:475–482Google Scholar
  452. Opie LH (1980a) Digitalis and sympathomimetic stimulants. Lancet 1:912–918Google Scholar
  453. Opie LH (1980b) Drugs and the heart. IV. Antiarrhythmic agents. Lancet 1:861–867Google Scholar
  454. O’Rourke RA, Henning H, Theroux P, Crawford MH, Ross J (1976) Favorable effects of orally administered digoxin on left heart size and ventricular wall motion in patients with previous myocardial infarction. Am Heart J Cardiol 37:708–715Google Scholar
  455. Packer M, Meller J, Gorlin R, Herman MV (1979) Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation 59:531–539PubMedGoogle Scholar
  456. Parmley WW, Braunwald E (1967) Comparative myocardial depressant and antiarrhythmic properties of d-propranolol, dl-propranolol and quinidine J Pharmacol Exp Ther 158:11–21PubMedGoogle Scholar
  457. Patart O, Desnos M, Leroy G, Lauru Y, Mogenet M, Garbay M, Barrillon A, Gerbaux A (1981) Nécrose hémorragique du tube digestif au cours d’une intoxication digitalique massive. Nouv Presse Med 10:1489–1491PubMedGoogle Scholar
  458. Perez HR (1970) Cardiac arrhythmia after succinylcholine. Anaesth Analg 49:33–48Google Scholar
  459. Perrier D, Mayersohn M, Marcus FI (1977) Clinical pharmacokinetics of digitoxin. Clin Pharmacokinet 2:292–311PubMedGoogle Scholar
  460. Perrone JP, Biostein R (1973) Asymmetric interaction of inside-out and rightside-out erythrocyte membrane vesicles with ouabain. Biochim Biophys Acta 291:680–689PubMedGoogle Scholar
  461. Peters U (1980) Klinische und pharmakologische Grundlagen für eine kontrollierte Digitalistherapie. Z Kardiol 69:247–261PubMedGoogle Scholar
  462. Peters U (1983) Dosierung von Herzglykosiden bei Niereninsuffizienz. In: Erdmann E (Hrsg) Therapie mit Herzglykosiden. Springer, Berlin Heidelberg New York, S 48–59Google Scholar
  463. Peters U, Kaiman SM (1978) Dihydrierte Metaboliten des Digoxins: Klinische Bedeutung und Nachweis verfahren. Z Kardiol 67:342–345PubMedGoogle Scholar
  464. Peters U, Falk LC, Kaiman SM (1978) Digoxin metabolism in patients. Arch Intern Med 138:1074–1076PubMedGoogle Scholar
  465. Peters U, Grabensee B, Grosse-Brockhoff F (1981a) Digitoxinapplikation bei chronischer Niereninsuffizienz. In: Kochsiek K, Rietbrock N (Hrsg) Digitalistherapie bei Herzinsuffizienz. Urban & Schwarzenberg, München Wien Baltimore, S 34–46Google Scholar
  466. Peters U, Risler T, Grabensee B, Falkenstein U (1981b) Untersuchungen zur Interaktion von Chinidin und Digitoxin. In: Kochsiek K, Rietbrock N (Hrsg) Digitalistherapie bei Herzinsuffizienz. Urban & Schwarzenberg, München Wien Baltimore, S 136–142Google Scholar
  467. Pierach C, Baur H (1979) Ist eine Dauerbehandlung mit Digitalisglykosiden sinnvoll? Dtsch Med Wochenschr 104:1251–1252PubMedGoogle Scholar
  468. Pitts BJR, Schwartz A (1975) Improved purification and partial characterization of (Na+, K+)-ATPase from cardiac muscle. Biochim Biophys Acta 401:184–195PubMedGoogle Scholar
  469. Presek P (1982) Spezifische Herzglykosidrezeptoren — Quantitative Aspekte der Bindung von g-Strophanthin an Zellmembranpräparationen verschiedener menschlicher Gewebe. Dissertation, Universität MünchenGoogle Scholar
  470. Proctor JD (1974) Zur individuellen Dosierung von Digitoxin und Digoxin. Medizin 8:215–218Google Scholar
  471. Pryzbyle AC, Paulay KS, Stein W, Damato AN (1974) Effects of digoxin on atrioventricular conduction patterns in man. Am J Cardiol 33:344–350Google Scholar
  472. Rader B, Smith WW, Berger AR, Eichna LW (1964) Comparison of the hemodynamic effects of mercurial diuretics and digitalis in congestive heart failure. Circulation 24:328–344Google Scholar
  473. Rahimtoola S, Gunnar R (1975) Digitalis in acute myocardial infartion: Help or hazard? Ann Intern Med 82:234–236PubMedGoogle Scholar
  474. Rav B, Cohn C, Eldridge F, Haucock E (1968) Left ventricular failure secondary to chronic pulmonary disease. Am J Med 45:229–241Google Scholar
  475. Repke KRH (1972) Biochemische Grundlagen der Entwicklung neuartiger Herzmittel des Digitalistyps. Pharmazie 27:693–700PubMedGoogle Scholar
  476. Repke KRH, Megges R (1973) Drug Latention — ein neues Wirkungsprinzip in der Therapie mit Herzglykosiden. Therapiewoche 27:2314–2318Google Scholar
  477. Repke K, Portius HJ (1963) Über die Identität der Ionenpumpen-ATPase in der Zellmembran des Herzmuskels mit einem Digitalis-Rezeptorenzym. Sep Exp 19:1–7Google Scholar
  478. Repke K, Est M, Portius HJ (1965) Über die Ursache der Speciesunterschiede in der Digitalisempfindlichkeit. Biochem Pharmacol 14:1785–1802PubMedGoogle Scholar
  479. Reuning R, Sams R, Notari R (1973) Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect, kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol 13:127–141Google Scholar
  480. Reuter H, Scholz H (1977) A study of the ion selectivity and the kinetic properties of the calcium-dependent slow inward current in mammalian cardiac muscle. J Physiol 264:49–62PubMedGoogle Scholar
  481. Richter M, Haustein K-O (1977) Binding of 16 α-gitoxin and its 16-acetate to human serum albumin. Eur J Clin Pharmacol 11:459–461PubMedGoogle Scholar
  482. Riecker G, Bolte H-D, Lüderitz B, Strauer BE (1978) Der kardiale Notfall. Ätiologische und pathophysiologische Grundlagen des akuten Myokardversagens. Verh Dtsch Ges Kreislaufforsch 44:79–98PubMedGoogle Scholar
  483. Rietbrock N Alken R (1980) Die Therapie der Herzinsuffizienz mit Digitalis. Dtsch Med Wochenschr 105:1622–1628PubMedGoogle Scholar
  484. Rietbrock N, Kewitz H (1980) Wahl des Herzglykosids. Muench Med Wochenschr 122:775–776Google Scholar
  485. Rietbrock N, Schüren KP (1978) Glykosidkonzentrationen, Glykosidwahl und Glykosidbedarf im Alter. Z Gerontol 11:433–445Google Scholar
  486. Rietbrock N, Woodcock BG (1981) On the rational choice of cardiac glycoside. TIPS, pp 206–209Google Scholar
  487. Rietbrock N, Guggenmos J, Kuhlmann J, Hess U (1976) Bioavailability and pharmacokinetics of β-methyldigoxin after multiple oral and intravenous doses. Eur J Clin Pharamacol 9:373–379Google Scholar
  488. Rietbrock N, Vöhringer HF, Kuhlmann J (1977) Der Metabolismus herzwirksamer Glykoside. Herz/Kreisl 9:825–832Google Scholar
  489. Rietbrock N, Alken RG, Ebert G (1979a) Vergleichende Untersuchungen der absoluten Bioverfügbarkeit von vier oralen Digoxin-Präparaten. Arzneimittelforsch 29:1724–1745Google Scholar
  490. Rietbrock N, Hoppe H-J, Kozma C, Vöhringer HF (1979b) Vergleich der absoluten Bio Verfügbarkeit von verschiedenen Digoxintabletten. Herz/Kreisl 11:470–473Google Scholar
  491. Rietbrock N, Woodcock BG, Kuhlmann J (1983) Nebenwirkungen und Interaktionen mit anderen Pharmaka. In : Erdmann E (Hrsg) Therapie mit Herzglykosiden. Springer, Berlin Heidelberg New York, S 76–98Google Scholar
  492. Risler T, Grabensee B, Grosse-Brockhoff F (1974) Eliminationskinetik und Dosierung von Digoxin bei Patienten mit Niereninsuffizienz. Dtsch Med Wochenschr 99:2130–2131PubMedGoogle Scholar
  493. Robinson JD (1975) Mechanisms by which Li+ stimulates the (Na+ + K+)-dependent ATPase. Biochim Biophys Acta 413:459–471PubMedGoogle Scholar
  494. Rodman T, Gorczyca CA, Pastor BH (1961) The effect of digitalis on the cardiac output of the normal heart at rest and during exercise. Ann Intern Med 55:620–31PubMedGoogle Scholar
  495. Rösch D, Weise HJ (1973) Elektrokardiographisches Bild der suizidalen Digitalisvergiftung beim Herzgesunden. Med Klin 68:1300–1303PubMedGoogle Scholar
  496. Rosen MR, Wit AL, Hoffman BF (1975) Electrophysiology and pharmacology of cardiac arrhythmias. IV. Cardiac antiarrhythmie and toxic effects of digitalis. Am Heart J 89:391–399PubMedGoogle Scholar
  497. Rossi B, Vuilleumier P, Gache C, Balerna M, Lazdunski M (1980) Affinity labeling of the digitalis receptor with p-nitrophenyltriazene-ouabain. A highly specific alkylating agent. J Biol Chem 255:9936–9941PubMedGoogle Scholar
  498. Rubinow A, Skinner M, Cohen AS (1981) Digoxin sensitivity in amyloid cardiomyopathy. Circulation 63:1285–1288PubMedGoogle Scholar
  499. Ruoho A, Kyte J (1974) Photoaffmity labeling of the ouabain-binding site on (Na+ + K+) adenosinetriphosphatase. Proc Natl Acad Sci 71:2352–2356PubMedGoogle Scholar
  500. Sabin G, Nebel W, Szurawitzki G, Schneider M (1981) Behandlung der schweren hämodynamischen Komplikationen des akuten Myokardinfarktes durch kombinierte Anwendung von Dopamin/Dobutamin und Nitroglycerin. Intensivmed 18:319–324Google Scholar
  501. Schatzmann HJ (1953) Herzglykoside als Hemmstoffe für den aktiven Kalium- und Natriumtransport durch die Erythrocytenmembran. Helv Physiol Acta 11:346–354Google Scholar
  502. Schenck-Gustafsson K, Dahlqyist R (1981) Pharmacokinetics of digoxin in patients subjected to the quinidine-digoxin interaction. Br J Clin Pharmacol 11:181–186PubMedGoogle Scholar
  503. Schmoldt A, Beuthe H, Haberland G (1975) Digitoxin metabolism by rat liver microsomes. Biochem Pharmacol 24:1639–1643PubMedGoogle Scholar
  504. Schneider KW, Gattenlöhner W (1971) Die unterschiedlichen Veränderungen der zentra1en Hämodynamik durch Digitalis-pur-purea- und Lanata-Präparate. Verh Dtsch Ges Inn Med 77:980–982PubMedGoogle Scholar
  505. Schneider J, Ruiz-Torres A (1977) Bedeutung des Körpergewichts für die Therapie mit Digoxin und Digoxinderivaten. Dtsch Med Wochenschr 102:116–118PubMedGoogle Scholar
  506. Schölmerich P, Pabst K, Jahrreis O, Lange P (1964) Nebenwirkungen der Therapie mit Herzglykosiden. Dtsch Med Wochenschr 89:12–18Google Scholar
  507. Scholz H (1979) Herzinsuffizienz. In: Fülgraff G, Palm D (Hrsg) Pharmakotherapie, Klinische Pharmakologie. Fischer, Stuttgart New York, S 37–52Google Scholar
  508. Scholz H, Hackbarth I, Schmitz W (1979) Intensität und zeitlicher Verlauf der Digitoxinwirkung im Vergleich zu anderen herzwirksamen Glykosiden am isolierten Warmblütlerherzen. In: Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 141–148Google Scholar
  509. Schüren KP, Hüttemann U (1974) Chronisch obstruktive Lungenerkrankungen: Die hämodynamische Wirkung von Digitalis beim chronischen Cor pulmonale in Ruhe und unter Belastung. Klin Wochenschr 52:736–746PubMedGoogle Scholar
  510. Schüren KP, Rietbrock N (1977) Klinische Aspekte der Digitalisintoxikation. Internist Prax 17:581–601Google Scholar
  511. Schüren KP, Kötter V, Schröder R (1980) Digitalis und koronare Herzkrankheit. Z Kardiol 69:271–328Google Scholar
  512. Schwartz A, Matsui H, Laughter AH (1968) Tritiated digoxin binding to (Na+ + K+)-ATPase: possible allosteric site. Science 159:323–325Google Scholar
  513. Schwartz A (1976a) Is the cell membrane Na+, K+-ATPase enzyme system the pharmacological receptor for digitalis? Circ Res 39:2–7Google Scholar
  514. Schwartz A (1976b) Sodium-potassium denosine triphosphatase — a receptor for digitalis? Biochem Pharmacol 25:237–239Google Scholar
  515. Schwartz A, Sordahl LA, Entman ML, Allen JC, Reddy YS, Goldstein MA, Luchi RJ, Wyborny LE (1973) Abnormal biochemistry in myocardial failure. Am J Cardiol 32:407–421PubMedGoogle Scholar
  516. Schwartz A, Lindenmayer G, Allen JC (1975) The sodium-potassium adenosine triphosphatase: pharmacological, physiological and biochemical aspects. Pharmacol Rev27:3–134PubMedGoogle Scholar
  517. Schwarzfischer P (1976) Serumglykosid-Spiegel im Alter. Probleme der Verlaufskontrolle bei Glykosid-Therapie. Fortschr Med 94:841–847PubMedGoogle Scholar
  518. Seiden R, Haynie G (1975) Ouabain plasma level kinetics and removal by dialysis in chronic renal failure. Ann Intern Med 83:15–19Google Scholar
  519. Seller RH, Cangiano J, Kim KE, Mendelssohn S, Brest AN, Swartz C (1970) Digitalis toxicity and hypomagnesemia. Am Heart J 79:57–68PubMedGoogle Scholar
  520. Seller RH, Greco J, Banach S, Seth R (1975a) Increasing the inotropic effect and toxic dose of digitalis by the administration of antikaliuretic drugs — further evidence for a cardiac effect of diuretic agents. Am Heart J 9:56–67Google Scholar
  521. Seller RH, Banach S, Namey T, Neff M, Swartz C (1975b) Cardiac effect of diuretic drugs. Am Heart J 89:493–500Google Scholar
  522. Sellers TD, Bashore TM, Gallaglur JJ (1977) Digitalis in the preexcitation syndrome. Analysis during atrial fibrillation. Circulation 56:260–267PubMedGoogle Scholar
  523. Selye H, Krajny M, Savoie L (1969) Digitoxin poisoning: Prevention by spironolactone. Science 164:842–843PubMedGoogle Scholar
  524. Selzer A (1981) Digitalis in cardiac failure. Arch Intern Med 141:18–19PubMedGoogle Scholar
  525. Selzer A, Cohn K (1970) Some thoughts concerning the prophylactic use of digitalis. Am J Cardiol 26:214–219PubMedGoogle Scholar
  526. Selzer A, Kelly JJ, Gerbode F, Kerth WJ, Osborn JJ, Poper RW (1966) Case against routine use of digitalis in patients undergoing cardiac surgery. JAMA 195:141–145Google Scholar
  527. Shanbour L, Jacobson E, Brobman G, Hinshaw L (1971) Effects of ouabain on splanchnic hemodynamics in the rhesusmonkey. Am Heart J 4:511–517Google Scholar
  528. Shapiro W, Narahara K, Taubert K (1970) Relationship of plasma digitoxin and digoxin to cardiac response following intravenous digitalization in man. Circulation 42:1065–1072PubMedGoogle Scholar
  529. Shapiro W (1978) Correlative studies of serum digitalis levels and the arrhythmias of digitalis intoxication. Am J Cardiol 41:852–859PubMedGoogle Scholar
  530. Sharpe DN, Norris RM, White BMCL (1975) Treatment with digoxin and measurement of serum digoxin levels after myocardial infarction. Br Heart J 37:530–533PubMedGoogle Scholar
  531. Shaw TRD (1978) Bioavailability studies: Their influence on the clinical use of digitalis. In: Bodem G, Dengler D (eds) Cardiac glycosides. Springer, Berlin Heidelberg New York, pp 187–195Google Scholar
  532. Siegel J, Sonnenblick E (1964) Quantification and prediction of myocardial failure. Arch Surg 89:1026–1032PubMedGoogle Scholar
  533. Simaan J, Fawaz G (1973) The effect of theophylline alone and in combination with ouabain on the isolated dog heart. Naunyn Schmiedebergs Arch Pharmacol 278:45–54PubMedGoogle Scholar
  534. Singer SJ, Nicolson GL (1972) The fluid mosaic model of cell membranes. Science 175:720–731PubMedGoogle Scholar
  535. Skou JC (1957) The influence of some cations on an adenosine triphosphatase from peripheral nerves. Biochim Biophys Acta 23:349–401Google Scholar
  536. Skou JC (1965) Enzymatic basis for active transport of Na+ and K+ across cell membranes. Physiol Rev 45:596–617PubMedGoogle Scholar
  537. Skou JC, Nørby JG (1979) Na, K-ATPase, Structure and kinetics. Academic Press, London New York San Francisco, pp 3–535Google Scholar
  538. Slany J, Mösslacher H (1976) Einfluß von Spirolactone auf die myokardiale Kaliumbilanz unter Strophanthin beim Menschen. Klin Wochenschr 54:671–676PubMedGoogle Scholar
  539. Smith TW (1975) Digitalis toxicity : Epidemiology and clinical use of serum concentration measurements. Am J Med 58:470–476PubMedGoogle Scholar
  540. Smith TW, Braunwald E (1980) The Management of heart failure. In: Braunwald E (ed) Heart disease. A textbook of cardiovascular medicine. Saunders, Philadelphia London Toronto, pp 509–570Google Scholar
  541. Smith TW, Haber E (1970) Digoxin intoxication: the relationship of clinical presentation to serum digoxin concentration. J Clin Invest 49:2377–2386PubMedGoogle Scholar
  542. Smith TW, Haber E (1973) Digitalis. Clinical value of the radioimmunoassay of the digitalis glycosides. Pharmacol Rev 25:219–228PubMedGoogle Scholar
  543. Smith TW, Butler VP, Haber E (1969) Determination of therapeutic and toxic serum digoxin concentrations by radioimmunoassay. N Engl J Med 281:1212–1216PubMedGoogle Scholar
  544. Smith TW, Willerson JT (1971) Suicidal and accidental digoxin ingestion. Report of five cases with serum digoxin level correlations. Circulation 44:29–36PubMedGoogle Scholar
  545. Smith TW, Wagner H, Strosberg AD, Young M (1974) Characterization of solubilized myocardial (Na+ + K+)-ATPase. Ann NY Acad Sci 242:53–68PubMedGoogle Scholar
  546. Smith TW, Haber E, Yeatman L, Butler VP (1976) Reversal of advanced digoxin intoxication with FAB fragments of digoxin-specific antibodies. N Engl J Med 294:797–800PubMedGoogle Scholar
  547. Sodums MT, Walsh RA, O’Rourke RA (1981) Digitalis in heart failure. Farewell to the foxglove? Clin Cardiol 246:158–160Google Scholar
  548. Sonnenblick EH, Williams JF, Glick G, Mason DT, Braunwald E (1966) Studies on digitalis XV. Effects of cardiac glycosides on myocardial force-velocity relations in the nonfailing human heart. Circulation 34:532–546PubMedGoogle Scholar
  549. Soyka LF (1981) Pediatric clinical pharmacology of digoxin. Pediatr Clin North Am 28:203–215PubMedGoogle Scholar
  550. Spannbrucker N, Vogel F, Kleinschmidt R, Klehr U (1981) Hämodynamische Auswirkungen einer Kombinationsbehandlung mit Dobutamin und Dopamin bei Patienten mit therapierefraktärer Herzinsuffizienz. Intensivmed 18:219–222Google Scholar
  551. Specter MJ, Schweizer E, Goldman RH (1975) Studies of magnesium’s mechanism of action in digitalis-induced arrhythmias. Circulation 52:1001–1005PubMedGoogle Scholar
  552. Starr I, Luchi RJ (1969) Blind study on the action of digotixin on elderly women. Am Heart J 78:740–751PubMedGoogle Scholar
  553. Staud R, Rietbrock N, Fassbender HP (1975) Excretion of methylproscillaridin in patients with a biliary fistula. Eur J Clin Pharmacol 9:99–1003PubMedGoogle Scholar
  554. Steinbeck G (1983) Kontraindikationen gegen die Digitalistherapie. In: Erdmann E (Hrsg) Therapie mit Herzglykosiden. Springer, Berlin Heidelberg New York, S 99–107Google Scholar
  555. Steinbeck G (1978) Zur Pathogenese von Herzrhythmusstörungen. Internist 19:200–206PubMedGoogle Scholar
  556. Steinbeck G, Bonke FIM, Allessie MA, Lammers WJEP (1980) The effect of ouabain on the isolated sinus node preparation of the rabbit studied with microelectrodes. Circ Res 46:406–414PubMedGoogle Scholar
  557. Steiness E (1973) Renal excretion of digoxin. In: Storstein O (ed) Symposium on digitalis. Gyldendal Norsk, Oslo, pp 178–182Google Scholar
  558. Steiness E (1978) Digoxin toxicity compared with myocardial digoxin and potassium concentration. Br J Pharmacol 63:233–237PubMedGoogle Scholar
  559. Stone JM, Fish C (1969) Digitalis toxicity: A review. J Indian Med Assoc 62:459–468Google Scholar
  560. Stopfkuchen H, Gilfrich HJ (1980) Symptome und Therapie der akuten Digitalisintoxikation im Kindesalter. Klinikarzt 9:15–17Google Scholar
  561. Storstein I (1974a) Renal excretion of digitoxin and its cardioactive metabolites. Clin Pharmacol Ther 16:14–24Google Scholar
  562. Storstein L (1974b) The influence of impaired renal function of the renal excretion of digitoxin and its cardioactive metabolites. Clin Pharmacol Ther 16:25–34Google Scholar
  563. Storstein L (1976) Studies on digitalis VII. Influence of nephrotic syndrome on protein binding, pharmakokinetics and renal excretion of digitoxin and cardioactive metabolites. Clin Pharmacol Ther 20:158–166PubMedGoogle Scholar
  564. Storstein L (1981a) Prospektive Untersuchungen zur Digitalis-Intoxikation. Fortschr Med 31–32:1247–1254Google Scholar
  565. Storstein L (1981b) The influence of age on digitoxin pharmacokinetics. In: Kochsiek K, Rietbrock N (eds) Digitalistherapie bei Herzinsuffizienz. Urban & Schwarzenberg, München Wien Baltimore, S 30–33Google Scholar
  566. Storstein L, Amlie J (1979) Pharmacokinetics and metabolism of digitoxin in patients with chronic active hepatitis. In: Greeff K, Rietbrock N (eds) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 191–198Google Scholar
  567. Storstein O, Hansteen V, Hatle L, Hilestad L, Storstein L (1977) Studies of digitalis. XIII. A Prospective study of 649 patients on maintenance treatment with digoxin. Am Heart J 93:434–443PubMedGoogle Scholar
  568. Storz H (1981) Über den klinischen Aussagewert von Glykosidkonzentrationsbestimmungen im Blutplasma. Herz/Kreisl 9:463Google Scholar
  569. Straub KD, Kane JJ, Bissett JK, Doherty JE (1978) Alteration of digitalis binding by quinidine: a mechanism of digitalis-quinidine interaction. Circulation [Suppl II] 58:58Google Scholar
  570. Strauer BE (1978) Das Hochdruckherz. Dtsch Med Wochenschr 103:1691–1695PubMedGoogle Scholar
  571. Strauer B (1982) Der Stellenwert der Vasodilatatoren in der Therapie der Myokardinsuffizienz. Dtsch Med Wochenschr 107:1026–1029PubMedGoogle Scholar
  572. Strauss HC, Bigger JT, Bassett AL, Hoffman BF (1968) Actions of diphenylhydantoin on the elctrical properties of isolated rabbit and canine atria. Circ Res 23:463–477PubMedGoogle Scholar
  573. Swann AC, Marini JL, Sheard MH, Maas JW (1980) Effects of chronic dietary lithium on activity and regulation of (Na+, K+)-adenosine triphosphate in rat brain. Biochem Pharmacol 29:2819–2823PubMedGoogle Scholar
  574. Szabo Z, Ritzl E (1981) Einfache Berechnung der Digoxindosierung bei Hyperthyreose. Der Krankenhausarzt 54:440–444Google Scholar
  575. Tackett RL, Holl JE (1981) Increased automaticity and decreased inotropism of ouabain in dogs with furosemide-induced hypomagnesemia. J Cardiovasc Pharmacol 3:1269–1277PubMedGoogle Scholar
  576. Taylor SA, Rawlins MD, Smith SE (1972) Spironolactone — a week enzyme inducer in man. J Pharm Pharmacol 24:578–579PubMedGoogle Scholar
  577. Taylor SH (1977) Heart failure-I. In: Hamer J (ed) Recent advances in cardiology. Churchill Livingstone, London Edinburgh, pp 369–398Google Scholar
  578. Ten Eick RE, Wyte SR, Ross SM, Hoffman BF (1967) Post-countershock arrhythmias in untreated and digitalized dogs. Circ Res 21:375–389PubMedGoogle Scholar
  579. Thadani U, Manyari D, Parker JO, Fung H-L (1980) Tolerance to the circulatory effects of oral isosorbide dinitrate. Rate of development and cross-tolerance to glyceryl trinitrate. Circulation 61:526–535PubMedGoogle Scholar
  580. Thomas JH (1971) The use and abuse of digitalis in the elderly. Geront Clin 13:285–295PubMedGoogle Scholar
  581. Tillement JP, Lhoste F, Giudicelly JF (1978) Diseases and drug protein binding. Clin Pharmacol 3:14–154Google Scholar
  582. Titus EO (1975) Characterization of pharmacological receptors. Naunyn Schmiedebergs Arch Pharmacol 288:269–281PubMedGoogle Scholar
  583. Towbin EG, Doherty JE, Ferrell CB (1964) Renal excretion of tritiated digoxin (localization). Circulation [Suppl III] 30:170Google Scholar
  584. Tritthart HA (1978) Neuere Aspekte der Wirkung von Herzglykosiden auf die elektrische und mechanische Aktivität des Myokards. Herz/Kreisl 10:211–217Google Scholar
  585. Unruh G V (1979) Bestimmung von Dihydrodigitoxin. In: Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 21–26Google Scholar
  586. Varomkov Y, Shell WE, Smirnov V, Jukovsky D, Chazov EI (1977) Augmentation of serum CPK activity by digitalis in patients with acute myocardial infarction. Circulation 55:719Google Scholar
  587. Vatner SF, Baig H, Manders WT, Muray PA (1978) Effects of a cardiac glycoside in combination with propranolol on the ischemic heart of conscious dogs. Circulation 57:568–572PubMedGoogle Scholar
  588. Vecsei P, Hackenthal E, Ganten D (1978) The renin-angiotensinaldosterone system. Past, present and future. Klin Wochenschr 56:3–46Google Scholar
  589. Vöhringer HF (1978) Pharmakokinetik von Digitoxin, Digitoxigenin, Monodigitoxosid und Digitoxigenin-didesoxyrhamnosid beim Menschen unter besonderer Berücksichtigung niereninsuffizienter Patienten. Habilitationsschrift, Universität BerlinGoogle Scholar
  590. Vöhringer HF (1981) Pharmakokinetik von Digitoxin im Vergleich zu Digoxin bei Niereninsuffizienz. In: Kochsiek K, Rietbrock N (Hrsg) Digitalistherapie bei Herzinsuffizienz. Urban & Schwarzenberg, München Wien Baltimore, S 21–29Google Scholar
  591. Vöhringer HF, Rietbrock N (1974) Metabolism and excretion of digitoxin in man. Clin Pharmacol Ther 16:796–806PubMedGoogle Scholar
  592. Vöhringer HF, Rietbrock N (1979a) Varianz der Digitoxinkonzentration im PlasmaEine Analyse der bestimmenden Faktoren. In : Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 61–67Google Scholar
  593. Vöhringer HF, Rietbrock N (1979b) Renale und extrarenale Elimination von Digitoxin. In : Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 114–115Google Scholar
  594. Vöhringer HF, Kuhlmann J, Rietbrock N (1976) Der Einfluß von Antacida auf die Plasmakonzentration von Digoxin beim Menschen. Dtsch Med Wochenschr 101:106–108PubMedGoogle Scholar
  595. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I (1975) Effect of chronic betaadrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022–1036PubMedGoogle Scholar
  596. Wagner JG (1974a) Appraisal of digoxin bioavailability and pharmacokinetics in relation to cardiac therapy. Am Heart J 88:133–138Google Scholar
  597. Wagner JG (1974b) Loading and Maintenance doses of digoxin in patients with normal renal function and those with severely impaired renal function. J Clin Pharmacol 14:329–338Google Scholar
  598. Wagner JG, Yates JD, Willis PW, Sakmar E, Stoll RG (1974) Correlation of plasma levels of digoxin in cardiac patients with dose and measures of renal function. Clin Pharmacol Ther 15:291–301PubMedGoogle Scholar
  599. Waldorff S, Damgaard Andersen J, Heebøll-Nielsen N, Nielsen OG, Moltke E, Sørensen U, Steiness E (1978) Spironolactone-induced changes in digoxin kinetics. Clin Pharmacol Ther 24:162–167PubMedGoogle Scholar
  600. Waldorff S, Hansen PB, Kjaergard H, Buch J, Egeblad H, Steiness E (1981) Amilorideinduced changes in digoxin dynamics and kinetics : Abolition of digoxin-induced inotropism with amiloride. Clin Pharmacol Ther 30:172–176PubMedGoogle Scholar
  601. Wallick ET, Lane LK, Schwartz A (1979) Biochemical mechanism of the sodium pump. Annu Rev Physiol 41:397–412PubMedGoogle Scholar
  602. Wambach G, Helber A, Saborowski F, Bönner G, Kaufmann W (1979) Zur Genese der Elektrolytstörungen nach schweren Digitalisintoxikationen. Herz/Kreisl 11:24–27Google Scholar
  603. Waser PG, Volkart O (1954) Wirkung von Herzglykosiden auf Aktomyosin. Helv Physiol Acta 12:12–22Google Scholar
  604. Weber DJ (1972) Intravenous triamterene in the treatment of acute digitalis intoxication. Clin Pharmacol Ther 13:868–874PubMedGoogle Scholar
  605. Weiner N (1980) Drugs that inhibit adrenergic nerves and block adrenergic receptors. In: Goodman A, Gilman A (eds) The pharmacological basis of therapeutics. MacMillan, New York, pp 176–210Google Scholar
  606. Weiner N (1980) Norepinephrine, epinephrine, and the sympathomimetic amines. In: Godman A, Gilman A (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 138–175Google Scholar
  607. Weinmann J, Hasford J, Kuhlmann J, Bippus PH, Lichey J, Rietbrock N (1979) Digoxinkonzentrationen in Plasma und Gewebe. Med Klin 74:613–619PubMedGoogle Scholar
  608. Weiss W, Teufel W (1979) Digitalisierungsprobleme im Alter. Ther Ggw 118:884–906PubMedGoogle Scholar
  609. Weissler AM (1974) Assessment of the left ventricular response to cardioactive agents by non-invasive techniques. In: Dengler HJ (ed) Symposia Medica Hoechst. Schattauer, Stuttgart New York, pp 5–18Google Scholar
  610. Weissler AM, Snyder JR, Schoenfeld GD, Cohen S (1966) Assay of digitalis glycosides in man. Am J Cardiol 17:768–780Google Scholar
  611. Weissler AM, Harris WS, Schoenfeld CD (1968) Systolic time intervals in heart failure in man. Circulation 37:149–159PubMedGoogle Scholar
  612. Wellens HJ, Durrer D (1973) Effect of digitalis on atrioventricular conduction and circus movement tachycardias in patients with Wolff-Parkinson-White-syndrome. Circulation 47:1229–1233PubMedGoogle Scholar
  613. Wellens HJ, Cats VM, Düren DR (1975) Symptomatic sinus node abnormalities following lithium carbonate therapy. Am J Med 59:285–287PubMedGoogle Scholar
  614. Wenkebach K (1914) Die unregelmäßige Herztätigkeit und ihre klinische Bedeutung. Engelmann, Leipzig, S 3–124Google Scholar
  615. Wettrell G, Anderson K-E (1975) Absorption of digoxin in infants. Eur J Clin Pharmacol 9:49–55PubMedGoogle Scholar
  616. Wheat MW (1980) Acute dissecting aneurysms of the aorta: diagnostic and treatment-1979. Am Heart J 99:373–387PubMedGoogle Scholar
  617. Wheat MW, Fla G, Burford TH (1961) Digitalis in surgery: Extension of classical indications. J Thorac Cardiovasc Surg 41:162–168PubMedGoogle Scholar
  618. White R, Chamberlain D, Howard M, Smith T (1971) Plasma concentrations of digoxin after oral administration in the fasting and postprandiol state. Br Med J 1:380–387PubMedGoogle Scholar
  619. Whittam R, Chipperfield AR (1973) Ouabain binding to the sodium pump in plasma membrane isolated from ox-brain. Biochim Biophys Acta 307:563–577PubMedGoogle Scholar
  620. Wilkerson RD (1981) Effects of digitalis glycosides on myocardial function. In: Wilkerson RD (ed) Cardiac pharmacology. Academic Press, New York London Toronto, pp 113–126Google Scholar
  621. Wilkerson R, Mockridge P, Massing G (1980) Effects of selected drugs on serum digoxin concentration in dogs. Am J Cardiol 45:1201–1210PubMedGoogle Scholar
  622. Williams JF, Mathew FB (1981) Effect of quinidine on positive inotropic action of digoxin. Am J Cardiol 47:1052–1055PubMedGoogle Scholar
  623. Williams JF, Klocke FJ, Braunwald E (1966) Studies on digitalis. XIII. A comparison of the effects of potassium on the inotropic and arrhythmiaproducing actions of ouabain. J Clin Invest 45:346–352PubMedGoogle Scholar
  624. Wirth KE, Frölich JC, Hollifield JW, Falkner FC, Sweetman BS, Oates JA (1976) Metabolism of digitoxin in man and its modification by spironolactone. Eur J Clin Pharmacol 9:345–354Google Scholar
  625. Wolf M, Braunwald E (1980) General anesthesia and noncardiac surgery in patients with heart disease. In : Braunwald E (ed) Heart disease. Saunders, Philadelphia London Toronto, pp 1911–1922Google Scholar
  626. Wynne J, Braunwald E (1980) The cardiomyopathies and myocarditides. In: Braunwald E (ed) Heart disease. Saunders, Philadelphia, pp 1437–1498Google Scholar
  627. Yamamoto S, Akera T, Brody TM (1979) Sodium influx rate and ouabain-sensitive rubidium uptake in isolated guinea pig atria. Biochim Biophys Acta 55:270–284Google Scholar
  628. Yankopoulos NA, Kawai C, Federici EE, Adler LN, Abelmann WH (1968) The hemodynamic effects of ouabain upon the diseased left ventricle. Am Heart J 76:466–480PubMedGoogle Scholar
  629. Yeh BK, Chiang BN, Sung P-K (1976) Antiarrhythmic activity of potassium canrenoate in man. Am Heart J 92:308–314PubMedGoogle Scholar
  630. Yoda S, Sarrif AM, Yoda A (1975) Structure-activity relationship of cardiaotonic steroids for the inhibition of sodium- and potassium-dependent adenosine triphosphatase. IV. Dissociation rate constants for complexes of the enzyme with cardiac oligodigitoxides. Mol Pharmacol 11:647–652PubMedGoogle Scholar
  631. Zahorsky R (1980) Action of semisynthetic digitoxin — and scillarenin-derivatives on the heart-lung-preparation of the cat. Naunyn Schmiedebergs Arch Pharmacol 311:R42Google Scholar
  632. Zilly W (1979) Digitoxin bei akuter und chronischer Leberinsuffizienz. In: Greeff K, Rietbrock N (Hrsg) Digitoxin als Alternative in der Therapie der Herzinsuffizienz. Schattauer, Stuttgart New York, S 199–212Google Scholar
  633. Zilly W (1981) Digitoxin bei Patienten mit Leber-Insuffizienz. In: Kochsiek K, Rietbrock N (Hrsg) Digitalistherapie bei Herzinsuffizienz. Urban & Schwarzenberg, München Wien Baltimore, S 57–65Google Scholar
  634. Zilly W, Richter E, Rietbrock E (1975) Pharmacokinetics and metabolism of digoxinand β-methyl-digoxin-12α-3H in patients with acute hepatitis. Clin Pharmacol Ther 17:302–309PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • E. Erdmann

There are no affiliations available

Personalised recommendations